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Breast cancer is one of the types of cancer that occurs in women frequently and 
most of the cancer deaths are due to metastasis. During cancer metastasis, the 
tumor epithelial cells lose their cell-cell contacts, acquire mesenchymal, migratory 
and invasive characteristics through epithelial-to-mesenchymal transition (EMT). 
Although many studies shed light on the mutations of ASXL family members in 
several cancers but the mechanism of action and the regulation remained poorly 
understood. ASXL1 is considered as a novel type of tumor suppressor in myeloid 
malignancies, which acts through the regulation of cell proliferation.  
In this study, we showed that the depletion of ASXL1 in normal mammary epithelial 
cells leads to the loss of epithelial characteristics and gain stem cell-like, migratory 
and metastatic properties, which is characterized by the increased expression of the 
mesenchymal markers and decreased expression of the epithelial markers. Global 
RNA-seq transcriptome analysis revealed an enrichment of gene signatures 
associated with a mammary stem cell phenotype and EMT pathways upon ASXL1 
knockdown. We also examined the genome-wide binding of ASXL1 via ChIP 
sequencing and identified a preferential occupancy of ASXL1 near transcriptional 
start sites of a subset of ASXL1 target genes. From our results, we found PTEN as a 
target gene and the depletion of PTEN promotes EMT phenotype.  
Depletion of ASXL1 decreases the enrichment of H3K4me3 at the promoters of 
target genes. ASXL1 is physically interacting with methyltransferase SET1 complex 
members (Cfp1 and Wdr82) and it might be required for the maintenance of the 
cellular expression of SET1 complex members (Cpf1 and Wdr82). Taken together, 





ASXL1 might promote transcription of a subset of ASXL1 affected genes either by 
directly binding to the target genes or through the active mark, H3K4me3 on the 
promoters. Further studies may provide additional insight which may be useful for 




















Breast cancer is one of the most common among all cancers in women and the 
second most frequent cause of cancer-related deaths in females worldwide. And 
more importantly, around 90% of them are caused by invasion and metastasis of the 
tumor cells. It also occurs, but rarely, in men. It accounts 23% of total cancer patients 
and 14% of all cancer deaths (Jemal, Bray et al. 2011). The breast is made up of 
glands which contain lobules and ducts. The most common type of breast cancer is 
ductal carcinoma. 
Cancer development generally begins with a series of molecular events that alter the 
properties of normal cells, which leads to abnormal cell growth and division. Normal 
cells consist of a sophisticated system to check and control cell overgrowth, which is 
dysregulated in the cancerous cells making them to proliferate in an uncontrolled and 
indefinite manner. The loss of growth control is a result of the accumulation of 
genetic abnormalities like mutations, deletions, translocation or amplification. The 
mutated or malfunctioning genes can be grouped into three classes, such as 
oncogenes, tumor suppressors and DNA repair genes. Oncogenes are a mutated 
version of proto-oncogenes which normally enhance cell division and prevent cell 
death. In contrast, tumor suppressors have opposite functions like inhibiting cell 
division or causing cell death. Aberrations in DNA repair genes cause inappropriate 
DNA repair, which leads to accumulation of mutations and cancer. Although the 
affected genes may differ between tumors, the cancer cells share most of the 
characteristics, such as changes in cell morphology, insensitivity to anti-growth 
signals, evasion of apoptosis, continuous division and gain of migratory, invasive and 





Traditionally, cancer was considered as a genetic disease, but it is now realized that 
a combination of epigenetic abnormalities and genetic alterations work together to 
promote cancer development and progression (Jones and Laird 1999, Feinberg, 
Ohlsson et al. 2006, Jones and Baylin 2007). 
1.1. Chromatin Structure and organization 
Eukaryotic cells contain approximately two-meters-long genomic DNA, which is 
compacted and packed in the form of chromatin into 10 µm nucleus. However, it can 
be  accessible to the cellular processes such as gene expression and regulation at 
the same time (Felsenfeld and Groudine 2003). 
Chromatin is a complex of DNA, histones and other proteins.  It is a highly ordered 
structure made up of arrays of nucleosomes that forms the genetic material of a cell 
(Burgoyne, Mobbs et al. 1976). The nucleosome is the repeating unit of chromatin 
that comprises of approximately 147 base pairs of DNA wrapped in about 1.67 turns 
around the octamer of core histones. The core histones that form the octamer are 
H2A, H2B, H3 and H4 and each present as two copies within the nucleosome 
(Kornberg 1974, Fletcher and Hansen 1996, Luger, Mader et al. 1997, Suganuma 
and Workman 2011). Core histones contain positively charged lysine and arginine 
residues and their basic nature that allows them to be wrapped by the negatively 
charged DNA, which help in maintaining the stability of nucleosome. Within the 
histone octamer, histone proteins are known to dimerize through a structural feature 
called, histone fold, which constitutes three alpha-helices. In addition to the histone 
fold, histone possesses N-terminal tails that project out of the nucleosome and are 





propensity to be modified post-translationally (Fletcher and Hansen 1996, Luger, 
Mader et al. 1997). 
Each nucleosome is joined to the other through a linker DNA (180-240 bp) which is 
in turn bound by a fifth type of histone called linker histone H1. The linker histones 
are highly basic and bind to the DNA in the nucleosome core particles through their 
globular domains and the linker DNA with their tails (Das, Lucia et al. 2009, Vempati, 
Jayani et al. 2010, Suganuma and Workman 2011). The linker histones play a major 
role in the secondary level of chromatin organization by connecting adjacent 
nucleosomes to form a fiber-like structure, chromatin (Allan, Cowling et al. 1981, 
Fletcher and Hansen 1996, Dutnall and Ramakrishnan 1997, Luger, Mader et al. 
1997, Thomas 1999) (Fig.1). 
 
Figure. 1: The structure of the nucleosome. The basic structure of chromatin, 
nucleosome comprises of an octamer of histones H2A, H2B, H3 and H4 as dimers. Histones 
are wrapped around by 147 base pairs of DNA. The two nucleosomes are joined together by 
linker DNA and H1 binds to adjacent nucleosomes. The histone tails undergo post-
translational modifications.  
The most striking property of chromatin is the way it is packed within a cell. 










nucleosomes are arranged as “beads on a string” which is further compacted into a 
thicker fiber with 30 nm diameter (Kornberg 1974, Marsden and Laemmli 1979, 
Turner 1993). The 30-nm fiber achieves a compaction of roughly 50-fold from the 
original DNA length, which is further packed to form the higher-order structures (Fig. 
2) (Henikoff 2000, Richards and Elgin 2002, Felsenfeld and Groudine 2003). 
Chromatin can be divided into two major states, “euchromatin” and 
“heterochromatin” Heterochromatin is a highly condensed form of chromatin that is 
inaccessible to DNA binding factors and transcriptionally inactive. In contrast, 
euchromatin is less condensed, open and easily accessible, comprises a high 
density of genes that are either actively transcribed or repressed (Owen-Hughes and 
Bruno 2004, Grewal and Elgin 2007). Heterochromatin is also known as a chromatin 
state that functions in controlling chromosomal stability and preventing mutations 








Figure. 2: Chromatin organization. DNA is wrapped around a histone octamer to form 
nucleosome and the two nucleosomes are connected by linker DNA to form 11 nm 
chromatin fiber. The chromatin fibers are condensed to form 30 nm fiber and then 







Short region of DNA
Nucleosomes as “beads on string”
Packed nucleosomes fiber 
Higher chromatin fiber 






1.2 Histone modifications 
In general, the core histones are subjected to different post-translational 
modifications in their N- and C-terminal tails, which are unstructured and freely 
accessible on the surface of the nucleosome core to various enzymatic machineries 
to act at specific amino acid residues (Luger, Mader et al. 1997, Jenuwein and Allis 
2001, Rando and Chang 2009). The post-translational modifications include 
methylation of lysine and arginine residues, acetylation of lysine residues and 
phosphorylation of serine and threonine residues, which are well studied. There is 
also poorly understood category of the post-translational modifications, which 
includes ubiquitination and sumoylation of lysine residues (Fig.3) (Fischle, Wang et 
al. 2003, Osley 2004, Yang 2005, Johnsen 2012). Acetylation and methylation are 
the most elaborately studied modifications. Their functional consequences and the 
domains that recognize them are also well studied along with the enzymes that carry 
out these modifications. These modifications extend the histone’s role in the 
regulation of processes like replication, transcription, recombination and repair 
besides scaffolding the chromatin structure (Jenuwein and Allis 2001).  
The combination of post-translational modifications of histones creates a complex 
set of signals defined as “histone code”.  Before the histone code was proposed, 
histones were simply thought as proteins required for DNA compaction. Now it has 
become evident that the DNA sequence alone can not decide all the outcomes of 







Figure. 3: Main post-translational histone modifications. Different types of post-
translational modifications occur at the NH2- terminal and COOH- terminal tails of the 
histones which define the chromatin state. Histone modifications include acetylation, 
methylation, ubiquitination, phosphorylation and sumoylation. Some of the modifications are 
shown here. Modified from (Cota, Shafa et al.) 
The “histone code” provides a specific binding site for selected effector proteins and 
can determine the cell fate by regulating key processes such as cell cycle, apoptosis 
and signal transduction (Strahl and Allis 2000, Jenuwein and Allis 2001, Latham and 
Dent 2007). Some histone modifications are associated with transcriptional silencing 
(H3K27me3) (Karpiuk, Najafova et al.) and others with activation (H3K4me3) (Strahl 
and Allis 2000, Bannister, Schneider et al. 2002). This function is mediated either 
directly by changing the physical or chemical properties of the chromatin fiber or 










































1.2.1 Chromatin modifying enzymes 
Epigenetic modifications (DNA and histones) play an important role in the regulation 
of hetero and euchromatin.  Epigenetic modifications remodel the chromatin either 
directly by influencing the nature of interactions with the DNA or by employing other 
non–histone proteins which regulate cell-specific gene expression or repression. The 
epigenetic regulators alter the chromatin structure and regulate its accessibility to the 
replication and transcriptional machinery (Luger, Mader et al. 1997, Horn and 
Peterson 2002, Narlikar, Fan et al. 2002). These modifications can be achieved by 
the specific types of enzymes and co-factors and they can be majorly classified into 
the following categories: “epigenetic writers” and “epigenetic erasers”. Epigenetic 
writers are the enzymes that catalyze the addition of chemical groups onto either 
histone tails or the DNA such as acetyl or methyl groups or ubiquitin moieties (e.g. 
histone lysine acetyltransferases, histone lysine/arginine methyltransferases, and 
ubiquitin ligases, DNA methyltransferases) (Campos and Reinberg 2009, Cedar and 
Bergman 2009). Epigenetic erasers are a group of enzymes that can remove the 
histone modifications (e.g. histone demethylases and histone deacetylases) 
(Kangaspeska, Stride et al. 2008, Metivier, Gallais et al. 2008). Misregulation of 
factors that mediate the deposition or removal of histone modifications leads to 
epigenetic imbalance, which causes cancer initiation, progression and metastasis.  
1.2.2 Chromatin binding proteins 
 “Epigenetic readers” are a special class of proteins that recognize and are recruited 
to the specific modifications on histones or nucleotides. Some of the well-studied 





domains and WDR40 for methylated lysine or arginine residues. (de la Cruz, Lois et 
al. 2005).  
Chromatin is a highly dynamic structure that is constantly remodeled to provide 
accessibility to several factors facilitating important biological processes. In addition 
to the chromatin modifiers, there are chromatin remodeling enzymes and histone 
chaperones.  that alter the chromatin architecture by removing, adding, moving or 
replacing histones in the chromatin (Strahl and Allis 2000, Loyola and Almouzni 
2004, Taverna, Li et al. 2007, Wilson and Roberts 2011). Chromatin remodeling is 
known to participate in various DNA transaction processes like replication, 
recombination, transcription, repair and chromatin assembly.  The chromatin 
remodeling complexes are classified into following families, such as SWI/SNF 
(switching defective/sucrose non-fermenting) family, the ISWI (imitation SWI) family, 
the NuRD (nucleosome remodeling and deacetylation)/Mi-2/CHD (chromodomain, 
helicase, DNA binding) family and the INO80 (inositol requiring 80) family (Morrison 
and Shen 2009, Hargreaves and Crabtree 2011).  
1.3 Cancer and metastatic progression 
Cancer metastasis is a complex and multistep process in which tumor cells 
disseminate from the primary tumor, migrate and survive during circulation, invade 
and adapt to the microenvironment of distant secondary site to form new tumors 
(secondary tumors) that result in the 90% of deaths in the cancer patients (Zajicek 





1.3.1 Epithelial-to-mesenchymal transition  
Epithelial-to-mesenchymal transition (EMT) is first identified in the development of 
the embryo and it plays an essential role in the early developmental processes such 
as gastrulation, mesoderm formation and neural crest development. During EMT, 
polarized, immotile epithelial cells transform their plasticity into a migratory 
mesenchymal phenotype by transient dedifferentiation (Wang and Zhou 2013, 
Lamouille, Xu et al. 2014). To undergo EMT, the epithelial cancer cell loses the 
expression of E-cadherin and cell-cell adhesion proteins such as claudin, occludins 
and Zonula occludes 1 (ZO1) (Huang, Guilford et al. 2012). The adherent junctions 
are destabilized by degradation of epithelial cadherin (E-cadherin) and repression of 
cytokeratins.  The down-regulation of E-cadherin is compensated by increased 
expression of mesenchymal neural cadherin (N-cadherin), fibronectin, Vimentin and 
facilitate cell migration and invasion (Maschler, Wirl et al. 2005, Kim, Litzenburger et 
al. 2007, Wheelock, Shintani et al. 2008, Yilmaz and Christofori 2009, Huang, 
Guilford et al. 2012). 
EMT is also involved in wound healing, tissue regeneration and organ fibrosis (Wang 
and Zhou 2013). In cancer, the differentiated epithelial tumor cells convert into 
differentiated mesenchymal cells through the EMT process. EMT phenotype is 
associated with a reduction in tumor growth, increased resistance to apoptosis, 
increased motility and invasiveness and enhanced metastatic ability (Kang and 
Massague 2004, Eccles and Welch 2007). 
During EMT, a set of genes, associated with cell adhesion, differentiation, migration 
and invasion, are transcriptionally altered which is achieved by several transcription 





Depletion of E-cadherin is an important characteristic of EMT during the 
development and cancer progression. SNAL1 repress CDH1 gene transcription by 
directly binding to the E-boxes of CDH1 promoter. In addition to SNAIL1, several 
other transcription factors are also capable of repressing E-cadherin transcription. 
SLUG, a close relative of SNAL1 and two other members of ZEB family- ZEB1 and 
ZEB2 also bind to the CDH1 promoter and downregulate the E-cadherin expression 
(Hennig, Behrens et al. 1995, Giroldi, Bringuier et al. 1997, Batlle, Sancho et al. 
2000, Cano, Perez-Moreno et al. 2000, Comijn, Berx et al. 2001, Hajra, Chen et al. 
2002, Eger, Aigner et al. 2005). These transcription factors act as transcriptional 
repressors and suppress the expression of E-cadherin and ZO-1, leading to the 
dissolution of cell-cell adhesions and tight junctions. Repression of epithelial markers 
is balanced by upregulation of mesenchymal markers, such as N-cadherin, Vimentin 
and fibronectin. N-cadherin upregulation stimulates the tumor metastasis and its 
expression is associated with poor survival. Vimentin is an intermediate filament 
which is involved in the migration and invasiveness and its expression is considered 
as a charcteristic of epithelial cells undergoing EMT (Franke, Grund et al. 1982, 
Nakajima, Doi et al. 2004).  Altogether, these changes enable the cells to switch 
from an epithelial phenotype to mesenchymal phenotype by regulating expression of 
epithelial markers to promote cell migration and invasion. 
1.3.2 Mesenchymal-to-Epithelial transition  
Mesenchymal-to-Epithelial transition (MET) is a reverse-EMT process in which 
motile, multipolar or spindle- shaped mesenchymal cells are transformed into 
polarized epithelial cells. In general, this process occurs after the cell reaches the 





embryo development or organogenesis (De Craene and Berx 2013, Nieto 2013). But 
in the case of cancer, the migrated mesenchymal tumor cells revert back into 
epithelial cells through MET process and form a secondary tumor (Peinado, Olmeda 
et al. 2007, Yang, Chen et al. 2009, Martin, Dwyer et al. 2010, Sun, Zhao et al. 
2010).  
EMT and MET consist the opposite processes by which cells switch between 
epithelial and mesenchymal phenotypes and play a vital role both in embryo 
development and organogenesis and in tumor metastasis. As the critical EMT event 
is the down-regulation or repression of E-cadherin, the reexpression of E-cadherin is 
an important hallmark of MET. (Fig.4). Both EMT and MET are dynamically balanced 
to maintain tissue homeostasis and development of embryo and metastatic cancer  
(Prindull 2005, Ricci-Vitiani, Lombardi et al. 2007, Thiery, Acloque et al. 2009) 
MET participate in the stability of distant metastases by making the cancerous cells 
regain epithelial properties and integrate into distant organs (Micalizzi, Farabaugh et 
al. 2010, Heerboth, Housman et al. 2015). MET is also an essential developmental 
process and well-studied in kidney organogenesis, cardiogenesis, hepatogenesis 
and somitogenesis (Nakajima, Yamagishi et al. 2000, Nakaya, Kuroda et al. 2004, Li, 
Zheng et al. 2011).  
1.3.3 Cancer stem cells and metastasis 
Cancer stem cells (CSCs) or tumor-initiating cells represent a small percentage of 
tumor cells that have an ability to self-renew and differentiate into cancer cells 






Figure. 4: EMT and MET in carcinogenesis and tumor metastasis. The transformed 
epithelial cell divide, grow and form a primary tumor. The epithelial cells are converted to 
mesenchymal cells through EMT process. Then the tumor cells disseminate from the 
primary tumor and enter into circulation (intravasation). The disseminated tumor cells exist 
the blood vessels (extravasation) and invade into the distant organ and the mesenchymal 
cells revert back into epithelial cells through MET to form a secodary tumor. Modified from 



























Similar to the normal stem cells, CSCs can also develop into different types of 
cancer cells in the tumor and hence termed as cancer stem cells. CSCs are capable 
of dictating invasion, oncogenesis, metastasis, tumor growth and cancer recurrence. 
Differentiated cancer cells were shown to proliferate faster than CSCs, but have the 
little tumor-initiating capacity (Chen, Kasai et al. 2012). CSCs can form new tumors 
when injected into immunodeficient mice (Chen, Yang et al. 2012). CSCs are first 
identified in leukaemia and have been reported in different cancers including  breast 
(Al-Hajj, Wicha et al. 2003), colon (Ricci-Vitiani, Lombardi et al. 2007), prostrate (Gu, 
Yuan et al. 2007), ovarian (Zhang, Balch et al. 2008), pancreas and other tissues 
(Lapidot, Sirard et al. 1994, Visvader and Lindeman 2008).  
CSCs can be identified by both CSC-specific cell surface marker expression and 
also by functionality assays, such as sphere formation and aldehyde dehydrogenase 
(ALDH) activity assays. The surface marker expression profile of CSCs, that 
promotes breast cancer metastasis, is CD44high/CD24low (Al-Hajj, Wicha et al. 2003). 
Signal transduction pathways of stem cell regulation also play an important role in 
carcinogenesis e.g. Notch, Sonic hedgehog (Gigi, Geiger et al.), and Wnt signaling. 
The traditional therapies used against cancer such as chemotherapy and 
radiotherapy are inefficient due to drug resistance of cancer cells and self-renewal 
properties of CSCs, which leads to cancer recurrence (Kopper and Hajdu 2004, 
Dragu, Necula et al. 2015).  
1.4 Epigenetics in cancer  
Cancer is initiated by genetic alterations such as mutations or by epigenetics, such 
as tumor suppressors and oncogenes, which regulate cell survival, proliferation and 





development and maintenance of tissue-specific gene expression. (Egger, Liang et 
al. 2004, Sharma, Kelly et al. 2010). Disruption of epigenetic processes alters gene 
expression and malignant cellular transformation  (Sharma, Kelly et al. 2010). The 
post-translational modifications of histones play a crucial role in regulating the 
accessibility of epigenetic regulators and transcription factors to the specific regions 
of chromatin. Tumorigenesis  is hypothesized that alteration in the epigenetic 
modifications leads to inappropriate expression or silencing of genes (oncogenes or 
tumor suppressors) (Chi, Allis et al. 2010). 
Following is a brief overview of different epigenetic modifications, the enzymes 
involved in maintaining their dynamics and their functional relevance. 
1.4.1 DNA methylation 
DNA methylation is one of the fundamental and most intensely studied epigenetic 
modifications, which plays an important role in regulating gene expression and stable 
gene silencing. DNA methylation is associated with histone modifications and 
regulate the genomic function by changing chromatin architecture. DNA methylation 
is a covalent modification of DNA that occurs at the cytosine residues in CpG 
dinucleotides, which form large clusters called CpG islands. DNA methylation is 
catalyzed by a family of DNA methyltransferases (DNMTs). CpG islands occupy 
approximately 60% of human gene promoters (Bird 2002, Takai and Jones 2002, 
Wang and Leung 2004).  
Cancer cells exhibit aberrant DNA methylation patterns such as hypo and 
hypermethylation, which can drive malignant transformation. Tumor suppressor 
genes are often silenced in tumor cells due to hypermethylation whereas oncogenes 





overexpressed in breast cancers. It was reported that DNA methylation silences 
several genes in breast cancer and thus affects several pathways involved in breast 
tissue homeostasis, including cell cycle regulation, tumor susceptibility, carcinogen 
detoxification and cell adhesion (Widschwendter and Jones 2002).   
E-cadherin (CDH1) was reported to be downregulated by DNA methylation 
promoting an invasive phenotype in prostate and other epithelial cancers. It was 
shown that hypermethylation of CpG island in the promoter region of the CDH1 
gene alters the expression of E-cadherin, leading to loss of tissue integrity which is 
an important step in tumor progression. (Caldeira, Prando et al. 2006, Keil, Abler et 
al. 2014). DNA methylation and histone modifications cooperate with each other to 
repress the target gene expression. E-Cadherin expression is significantly 
downregulated by suppressing demethylation of histone H3 on lysine 9 (H3K9me2) 
and DNA methylation by an interaction of  EMT-TF, SNAIL with G9a and DNA 
methyltransferases (DNMTs) and recruits to the promoters (Dong, Wu et al. 2012). It 
was also reported that DNA methylation is involved in the generation of CSCs 
(Esquela-Kerscher and Slack 2006, Volinia, Calin et al. 2006). Altogether, alteration 
in DNA methylation plays an important role during the EMT induction. 
1.4.2 Histone modifications and their functional consequences  
Alteration in the post-translational modifications of histones contributes to the 
repression of tumor suppressor genes and the activation of oncogenic genes. 
Several histone readers and writers are mutated or transcriptionally altered in 
tumors. Histone modifications like acetylation, methylation and ubiquitination were 
shown to be associated with several disorders and cancers (Fraga and Esteller 





1.4.2.1 Histone acetylation 
Histone acetylation is a reversible, very dynamic and well-characterized modification 
which is involved in chromatin structure, transcription, DNA repair and cancer 
progression (Wang, Allis et al. 2007, Choudhary, Kumar et al. 2009). Histone 
acetylation is a chemical reaction carried by various histone acetyltransferases 
(HATs), which transfer the acetyl group from acetyl coenzyme A (acetyl-CoA) to the 
ε-amino group of the lysine residues of histone proteins. Histone acetylation is 
generally associated with a more open chromatin structure and active transcription. 
The acetylation of histones neutralizes the positive charge of lysines, which can 
potentially reduce the interaction between DNA and histones and thereby increases 
DNA accessibility to the transcription factors (Imhof, Yang et al. 1997). Histone 
acetylation regulates many cellular processes and the unique acetylation marks 
either alone or in combination lead to distinct outcomes (Grunstein 1997, Tropberger 
and Schneider 2010).  
The most prominent members of the acetyl transferases are the GNAT (Gcn5-
related N-acetyltransferases), CBP/p300 and MYST 
(MOZ/YBF2/SAS2/TIP60/HBO1) families. Broadly each of these enzymes is capable 
of modifying different lysine residues of histones.  HATs can act as tumor 
suppressors and control cell cycle progression and proliferation. They can also 
function as oncogenes and activate malignant genes by altering acetylation profile 
and contribute to cancer (Di Cerbo and Schneider 2013). The HAT, p300 promotes 
EMT and tumor progression by affecting the regulation of SNAIL and ZEB1 in colon 





acetylate the oncogene c-MYC and leads to cancer progression (Patel, Du et al. 
2004).  
1.4.2.2 Histone deacetylation 
Deacetylation is a reverse reaction to acetylation, catalyzed by  Histone 
deacetylases (HDACs), which restores the positive charge of the lysine residues. 
Histone deacetylation potentially results in chromatin compaction and transcriptional 
repression (Yang and Seto 2007). Eighteen mammalian HDACs are reported till now 
and are categorized  into four major classes based on their sequence homology and 
cofactor dependency. Class I includes HDACs 1, 2, 3 and 8 (similar to yeast Rpd3), 
Class II consists HDAC 4, 6, 7, 9 and 10 (similar to yeast Hda1), Class III includes 
sirtuins, SIRT1-7(similar to yeast Sir2) and class IV consists of HDAC 11 (Ropero 
and Esteller 2007).  
Loss of histone acetylation is not only involved in carcinogenesis but also in tumor 
invasion and metastasis (Yasui, Oue et al. 2003). Like HATs, HDACs are also 
important for breast cancer development. HDAC1 plays an important role in TGFβ1 
induced EMT and inhibition of HDAC1 suppress TGFβ1 induced EMT (Yoshikawa, 
Hishikawa et al. 2007, Lei, Zhang et al. 2010). HDAC3 interacts with a component of 
histone methyltransferase complex, WDR5 and induces hypoxia-mediated EMT by 
regulating acetylation and methylation patterns on EMT genes. SIRT1 was shown to 
interact with ZEB1 and repress CDH1 expression by deacetylation of its promoter 
(Wu, Tsai et al. 2011, Byles, Zhu et al. 2012). HDAC1/2 complex cooperates with 






1.4.2.3 Histone methylation  
Histone methyltransferases (HMTs) transfer methyl groups from S-adenosyl 
methionine to the side chain of lysine and arginine residues. As methyl groups do not 
carry any charge on them, histone methylation does not alter the overall charge of 
the histone proteins. Lysines residues may be mono-, di-, or tri-methylated whereas 
arginines may be mono-, symmetrically or asymmetrically dimethylated (Bedford and 
Clarke 2009). The methyltransferases are classified into arginine (PRMTs) or lysine 
(KMTs) methyltransferases depending on the methylation of the amino acid residue. 
SET domain is the catalytic subunit of all histone methyltransferases (HMTs) such as 
G9a, EZH1/2, SUV39H1/H2, except for the DOT1L, H3K79 methyltransferase, and 
transfer methyl group (Miller, Krogan et al. 2001, Wang and Shang 2013).  Lysines 
4, 9, 27, 36 and 79 of histone H3 and 20 of histone H4 are methylated by lysine 
methyltransferases. Histone methylation is known to be associated with either 
transcriptional activation or repression depending upon the position of the amino acid 
residue modified.  For example, trimethylation of histone H3 at K4 (H3K4me3), K79 
(H3K79me3) and K36 (H3K36me3) are considered as active marks, whereas 
H3K9me2, H3K9me3 and H3K27me3 are considered as transcriptional repressive 
marks (Kouzarides 2007).  
Histone methylation is important for proper genome programming during 
development. Misregulation of methylation machinery can lead to diseased states 
such as cancer. Several studies reported that altered histone methylation might play 
a role in cancer, tumor recurrence and poor survival (Albert and Helin 2010, Chi, Allis 
et al. 2010). Aberrant regulation of G9a (H3K9 methyltransferase) was identified in 





and DNMTs to the CDH1 gene promoter to modulate CDH1 expression (Dong, Wu 
et al. 2012). It is also reported that Suv39H1 can  trimethylate H3K9 on the CDH1 
promoter (Serrano-Gomez, Maziveyi et al. 2016). Other methyltransferases, MMSET 
can di- or trimethylate H3K36 at the TWIST promoter whereas SET8 methylates 
H420 at the CDH1 and CDH2 promoters (Serrano-Gomez, Maziveyi et al. 2016). 
Mesenchymal markers are marked with H3K4me3 by WDR5, part of MLL and SET1 
HMT complex upon hypoxia (Wu, Tsai et al. 2011). The PRC2 complex which 
contains methyltransferase along with EED and SUZ12 plays a crucial role in 
transcriptional silencing by a repressive mark, H3K27me3 in carcinogenesis and 
EMT (Orlando 2003, Herranz, Pasini et al. 2008) 
1.4.2.4 Histone demethylation  
Since methylation is a very specific and stable mark, it was initially thought to be an 
irreversible modification until the discovery of the lysine demethylase, LSD1 or 
KDM1A which can remove mono and dimethyl groups from K4 of histone H3 
(H3K4me1/2), leading to transcription repression (Shi, Lan et al. 2004). JMJD6, a 
jumonii domain containing protein is the first arginine demethylase, which can 
demethylate methyl group from R2 and R3 of histone H3 (Chang, Chen et al. 2007). 
LSD1 is recruited to the epithelial gene promoters and repress the gene expression 
by removing the methyl groups from the H3K4me2 by interacting with EMT-TF, 
SNAIL (Lin, Ponn et al. 2010, Amente, Lania et al. 2013, Ferrari-Amorotti, Fragliasso 
et al. 2013). A histone H3K4 demethylase, KDM5B increases the expression of 
transcription factors ZEB1 which further downregulates the E-cadherin expression 
and upregulates the mesenchymal marker genes (Enkhbaatar, Terashima et al. 





demethylate H3K27me3 and H3K9me3 respectively and were shown recently to 
promote EMT (Ramadoss, Chen et al. 2012, Zhao, Li et al. 2013).  
1.4.2.5 Histone ubiquitination 
Ubiquitination is a basic biochemical process of covalent attachment of one or more 
ubiquitin molecules to lysine residues of proteins or to existing ubiquitin molecules on 
a protein. Ubiquitination is catalyzed by the sequential action of three enzymes, E1 
ubiquitin-activating, E2 ubiquitin-conjugating and E3 ubiquitin-ligase enzymes 
(Hershko and Ciechanover 1998, Sadowski and Sarcevic 2010). Ubiquitination 
controls the protein functions, such as degradation and subcellular localization 
(Pickart and Eddins 2004). Monoubiquitination can regulate DNA repair and gene 
expression but polyubiquitination through UbK48 targets proteins for proteasome 
degradation (Passmore and Barford 2004). 
H2A monoubiquitination is carried by PRC1 complex, which comprises RING1A and 
RING1B (Wang, Wang et al. 2004, Cao, Tsukada et al. 2005). H2B 
monoubiquitination is performed by RNF20/40 heterodimer (Zhu, Zheng et al. 2005). 
Ubiquitination plays a vital role in PRC-mediated silencing (Niessen, Demmers et al. 
2009). Both histones, H2A and H2B are monoubiquitinated at K119 (H2Aub1) and 
K120 (H2Bub1) respectively. H2Aub1 is associated with heterochromatin and 
prevents transcription elongation, whereas H2Bub1 is localized to euchromatin and 
promotes transcription elongation (Wang, Wang et al. 2004, Cao, Tsukada et al. 
2005, Xiao, Kao et al. 2005, Shukla, Stanojevic et al. 2006, Minsky, Shema et al. 
2008). H2Bub1 physically disrupt chromatin structure and makes DNA accessible to 
transcription factors and DNA repair proteins and plays a vital role in transcription, 





Decreased H2Bub1 levels were reported to be associated with tumor progression 
and tumor invasion (Shema, Tirosh et al. 2008, Prenzel, Begus-Nahrmann et al. 
2011, Johnsen 2012). Global H2Bub1 levels are either decreased or absent in 
advanced cancers such as breast, lung, colorectal and parathyroid cancers. The 
components of the PRC1 complex ubiquitinates H2A and promotes EMT by 
upregulating SNAIL through regulating PI3K/Akt/GSK-3β signaling pathway and also 
targets other EMT-TFs, Twist1 and ZEB1 (Song, Li et al. 2009, Wellner, Schubert et 
al. 2009, Yang, Hsu et al. 2010). 
1.4.2.6 Deubiquitination  
As other histone modifications, ubiquitination is also a reversible process and the 
removal of ubiquitin molecules is termed as deubiquitination which is performed by 
deubiquitinases (DUBs). There are around 100 DUBs encoded by the human 
genome, which are classified into 5 families. They are ubiquitin C-terminal 
hydrolases (Firestein, Bass et al.), ubiquitin-specific proteases (USPs), ovarian 
tumor domain DUBs, machado Joseph domain DUBs and JAB1/MPN 
metalloenzyme. The activity of these enzymes affects the half-life, activity and 
localization of multiple proteins, which in turn regulate cell homeostasis, protein 
stability and signaling pathways. DUBs can also be categorized into oncogenes or 
tumor suppressors as they regulate the activity of the other proteins involved in 
tumor development and progression (Fraile, Quesada et al. 2012).   EMT-TFs such 
as Snail/Slug, ZEB1/ZEB2, and Twist1 protein levels are tightly controlled by the 
ubiquitin-proteasome system (UPS) and several E3 ubiquitin ligases are shown to 
play crucial roles in the regulation of EMT. Genetic aberrations and alterations of 





(Ubiquitin-specific-protease-22), an H2B deubiquitinating enzyme is upregulated in 
tumors with a stem cell-like phenotype exhibiting a poor patient outcome (Glinsky, 
Berezovska et al. 2005, Zhang, Varthi et al. 2008, Inoue, Itoh et al. 2016). BAP1 
(BRCA1-Associated Protein 1), an H2A deubiquitinating enzyme, is reported as a 
tumor suppressor and its expression showed a negative correlation with 
tumorigenesis in lung cancer (Shen, Wang et al. 2016). Another report showed that 
H2A DUB, USP3 depletion induces mesenchymal cellular phenotype in A549 
epithelial lung cells (Nicassio, Corrado et al. 2007, Buus, Faronato et al. 2009). 
1.5 Role of signaling pathways in EMT  
Several molecular signaling pathways play an important role in cancer development, 
progression and  maintenance of CSC phenotype. Cell signaling pathways such as 
Wnt-β-catenin, Notch, transforming growth factor β (TGFβ), Sonic Hedgehog (Gigi, 
Geiger et al.), PI3K/Akt and Hypoxia are involved in the progression of EMT. These 
pathways are activated by various dynamic stimuli from the microenvironment, 
including cytokines, hypoxia etc.  
1.5.1 TGF-β signaling pathway 
Transforming growth factor-β (TGF-β) signaling is a well-studied pathway and plays 
a crucial role in diverse cellular processes like proliferation, apoptosis, differentiation 
and development.  Misregulation of TGF-β leads to defects in developmental 
processes, organ fibrosis and cancer.  TGF-β acts as a tumor suppressor in normal 
cells. Interestingly, it functions as a tumor promoter in advanced cancers. (Derynck 
and Akhurst 2007, Guo and Wang 2009, Nagaraj and Datta 2010).  The signaling is 
initiated by TGF-β binding to the transmembrane receptors that have 





TGF-β receptor I is recruited into the complex and  phosphorylated. This leads to the 
phosphorylation of  the C-terminus of the receptor-regulated Smad proteins (R-
Smads). The activated R-Smads interact with other Smads (Co-Smads), Smad 4 
and the Smad complex is translocated into the nucleus where it directly binds to the 
DNA and regulates TGF-β target gene expression along with other DNA binding 
factors, like ZEB, SNAIL and Twist (Massague 2000, Shi and Massague 2003, 
Zavadil and Bottinger 2005, Gomis, Alarcon et al. 2006, Fuxe, Vincent et al. 2010). 
This results in the decreased expression of epithelial markers, E-cadherin and 
cytokeratins and upregulation of mesenchymal markers, Vimentin, N-cadherin and 
fibronectin. 
TGF-β is a potent driver of cancer progression through EMT induction which in turn 
is associated with metastatic cancer (Wood, Parsons et al. 2007, Jones, Zhang et al. 
2008, Lamouille, Xu et al. 2014). TGF-β stimulation in normal and transformed 
mammary epithelial cells generates cells with the capacity to propagate new tumor 
(Mani, Guo et al. 2008). TGF-β induced EMT can also regulate cancer cells to de-
differentiate and gain CSC properties (Caja, Bertran et al. 2011, Fernando, 
Malfettone et al. 2015) . Mutations in the genes encoding TGF-β receptors and 
Smads can also result in carcinogenesis (Samanta and Datta 2012, Katsuno, 
Lamouille et al. 2013). 
1.5.2 Notch signaling pathway 
Notch signaling pathway is important for maintaining a balance between cell 
proliferation and apoptosis. Notch signaling regulates several cellular processes like 
cell proliferation, differentiation, development and cell death. It also affects the 





embryonic development, angiogenesis, cardiac homeostasis and bone regeneration. 
It is also essential for the development of normal mammary gland (Miele and 
Osborne 1999, Miele 2006, Miele, Miao et al. 2006, Pannuti, Foreman et al. 2010, 
Ranganathan, Weaver et al. 2011). Activation of Notch signaling starts with the 
interaction between ligands such as Delta-like (Delta-like-1, -3 and -4) and Jagged 
(Jagged1 and Jagged2) and Notch receptors (Notch1-4) (Nichols, Miyamoto et al. 
2007, Van de Walle, De Smet et al. 2011).  After binding to the ligand, the Notch 
receptor’s intracellular domain (NCID) is cleaved and released, which is then 
translocated to the nucleus and regulates the transcription complexes 
(CBF1/CSL/RBPjk/Su(H)) (Komatsu, Chao et al. 2008). 
Alteration in the Notch signaling pathway is associated with a range of multiple 
human disorders from developmental syndromes to adult onset diseases and 
cancer. Overexpression of Notch1 and their ligand jagged1 was observed in breast 
cancer, bladder cancer leukemia and prostate cancer (Miele and Osborne 1999, 
Miele 2006, Wang, Banerjee et al. 2006, Wang, Zhang et al. 2006). Overexpression 
of Notch-1 induces Snail and promote EMT. Notch stimulates the Slug promoter, 
which results in the upregulation of Slug and EMT initiation (Timmerman, Grego-
Bessa et al. 2004, Niessen, Fu et al. 2008). Dysregulation of this pathway causes 
several malignancies such as T-cell leukemia and breast cancer (Gallahan and 
Callahan 1997, Grabher, von Boehmer et al. 2006) 
1.5.3 PI3K/Akt signaling pathway 
Phosphatidylinositol 3-kinase (PI3K)/Akt pathway plays a vital role in regulating 
several biological processes such as cell proliferation, cell growth, metabolism, 





Kigawa et al. 2001). PI3K/Akt pathway is a multistep process, which is modulated by 
various proteins, including PI3K, phosphoinositide-dependent kinase 1 (PDK), 
phosphatase and tensin homolog (PTEN) and heat-shock protein 90 (HSP90). PI3K 
phosphorylates phosphatidylinositol 4,5-biphosphate (PI(4,5)P2) to 
phosphatidylinositol 3,4,5-triphosphate (PIP3) which recruits Akt to the membrane. At 
the membrane, Akt is activated by PDK1 which leads to the translocation of Akt to 
the nucleus.  Akt mediates several cellular processes such as apoptosis, cell 
proliferation, transcription, and cell migration and it also plays a vital role in 
promoting cell survival. 
Dysregulation of PI3K/Akt pathway is implicated in several diseases such as 
diabetes, cancer, cardiovascular and neurological disorders. Genes in the PI3K/Akt 
pathway are frequently altered in several human cancers. Akt1 is frequently 
activated in breast, prostate and ovary cancers. Akt2 is overexpressed in ovarian, 
pancreatic, breast and thyroid cancers (Cheng, Godwin et al. 1992, Bellacosa, de 
Feo et al. 1995, Ringel, Hayre et al. 2001, Testa and Bellacosa 2001). PTEN is 
frequently mutated or depleted in various cancers (Grille, Bellacosa et al. 2003, 
Mayer and Arteaga 2016). Akt has been shown to repress the expression of E-
cadherin and upregulate the expression of EMT inducers, Snail, Slug, BMI-1 and 
EZH2 which in turn promote EMT and CSC phenotype (Huang, Zhang et al. 2011, 
Dong, Konno et al. 2014). As a result of these somatic alterations, PI3K/Akt pathway 
is aberrantly activated and is associated with cellular transformation, tumorigenesis, 





1.5.4 Wnt signaling pathway 
Wnt is an extremely conserved developmental signaling pathway. Wnt proteins are 
secreted ligands that act as local mediators to regulate many aspects of 
development in all animals. The Wnt signaling pathway regulates cell proliferation, 
morphology, cell-contacts, migration and structural remodeling (Cadigan and Nusse 
1997, Reya and Clevers 2005). Wnt signaling is important for activating multiple 
intracellular pathways related to cell proliferation, differentiation and polarity. This 
pathway propagates through either canonical pathway or non-canonical pathway 
(Bhanot, Brink et al. 1996, Yang-Snyder, Miller et al. 1996, He, Saint-Jeannet et al. 
1997).  The wnt proteins interact with the transmembrane receptor, Frizzled (FZD) 
(along with co-receptor LRP), which activates Disheveled (Dvl) results in the 
formation of the activated receptor complex. The complex then triggers removal of 
the multifunctional kinase GSK-3β from a regulatory complex (APC/Axin/ GSK-3β). 
Stabilized β-catenin then translocates to the nucleus, where it binds to LEF/TCF 
transcription factors to activate transcription of the target genes (Pandur, Maurus et 
al. 2002, Logan and Nusse 2004).  
Wnt pathway plays a vital role in both developmental and cancer-related EMTs 
(Heldin, Vanlandewijck et al. 2012). Wnt signaling also plays a basic role in 
reprogramming and maintenance of CSC phenotype that is activated by EMT. 
Mutations in Wnt genes or components of Wnt pathway results in cancer 
progression, including tumor initiation, tumor growth, cell senescence, cell death, 
differentiation and metastasis. Aberrant Wnt signaling was reported to be associated 
with several tumors (Anastas and Moon 2013, Kim and Kahn 2014). β-catenin, along 





(Easwaran, Pishvaian et al. 1999, ten Berge, Koole et al. 2008). Abnormal activation 
of Wnt/β-catenin pathway also strongly correlates with carcinogenesis and cancer 
progression through maintaining cancer initiating cells (CICs) (Nguyen, Vanner et al. 
2012). 
1.6 Additional Sex Comb-Like (ASXL), transcription regulator  
The Additional Sex Combs-like (ASXL) genes such as ASXL1, ASXL2 and ASXL3 
are the mammalian homologues of the Drosophila gene, Addition of sex combs (Asx) 
(Fisher, Berger et al. 2003, Katoh and Katoh 2003, Katoh and Katoh 2004). The Asx 
protein has dual roles in the transcriptional regulation of homeotic and non-homeotic 
genes as a cofactor of both the Polycomb group (PcG) repressor complex and the 
Trithorax-group (trxG) activator complex and is involved in the transcriptional 
repression and activation of target genes in a context-dependent manner (Sinclair, 
Milne et al. 1998, Gildea, Lopez et al. 2000, Brock and van Lohuizen 2001, Dietrich, 
Moore et al. 2001, Grimaud, Negre et al. 2006, Halachmi, Schulze et al. 2007, 
Petruk, Smith et al. 2008). ASXL1 and ASXL2 are expressed in a wide variety of 
mammalian tissues but ASXL3 expression is confined to the brain and the eye 
(Fisher, Randazzo et al. 2006, Bainbridge, Hu et al. 2013, LaFave, Beguelin et al. 
2015).  
1.6.1 Structure of ASXL1 protein 
The ASXL family proteins share common domains that include, an ASXN helix-turn-
helix domain in the N-terminal region, an ASXH globular domain in the N-terminal 
adjoining region, ASXM1 and ASXM2 domains in the central part and a PHD domain 
in the C-terminal region. The full length human ASXL1 codes for a nuclear protein of 





domain and it is structurally similar to the Forkhead-box (FOX) domain of FOXA3, 
FOXK1, FOXO1 and FOXO4, which regulates transcription and DNA repair during 
embryogenesis and carcinogenesis. (Sanchez-Pulido, Kong et al. 2012, Katoh 
2013). The ASXH domain directly binds to the H2A deubiquitinating enzyme BAP1, 
an ubiquitin carboxy-terminal hydrolase (UCH) (Scheuermann, de Ayala Alonso et al. 
2010) and Lysine Specific Demethylase-1A (LSD1/KDM1A) (Lee, Cho et al. 2010, 
Sanchez-Pulido, Kong et al. 2012). The ASXM1 and ASXM2 domains are protein-
protein interacting domains, which directly binds to the nuclear hormone receptors 
(NHRs) such as RAR, RXR, ER, AR, GR and TR as well as to the NHR-coactivator 
NCOA1. ASXM2 domain consists of the LVxxLL motif. (Cho, Kim et al. 2006, 
Grasso, Wu et al. 2012). And the PHD domain is a histone- or DNA-binding domain 
of chromatin regulators and transcription factors (Sanchez and Zhou 2011, Li and Li 
2012, Liu, Qin et al. 2012). The functional divergence between ASXL1 and ASXL2 is 
due to the presence of CBX5 (HP1α)-binding PxVxL motif in ASXL1 and ASXL3, but 






Figure. 5: Schematic representation of ASXL1 protein structure. Human ASXL1 
encodes a 1541 amino acid protein. The ASXN and PHD domains bind to modified histones 
or DNA. The ASXH, ASXM1 and ASXM2 domains are binding modules for BAP1, LSD1 
(KDM1A), NCOA1 and NHRs. CBX5 * indicates that CBX5 binds to ASXL1, but not to 
ASXL2 (modified from Katoh 2013). 
ASXL1 contains a number of putative motifs, such as nuclear localization sequences 
(NLSs), PEST (proline (P), glutamate (E), serine (S) and threonine (T)) sequences , 
cyclin interaction substrate recognition sites and phosphorylation sites for cyclin-
dependent kinases (CDKs) (Fisher, Randazzo et al. 2006).  
1.6.2 Functions of ASXL1  
ASXL family members are scaffolding proteins that recruit epigenetic regulators and 
transcription factors to specific genomic loci with specific histone modifications. 
ASXL proteins have divergent functions in developing tissues. ASXL1 is highly 
expressed in the developing and adult hematopoietic cells and depletion of ASXL1 
leads to misregulation of hematopoietic progenitor proliferation and differentiation 
(Fisher, Pineault et al. 2010, Abdel-Wahab, Gao et al. 2013, Wang, Li et al. 2014). 




































































in mice (Fisher, Lee et al. 2010). ASXL1 is required for the maturation of lung and 
development of eye and cardiovascular system. ASXL1 interacts with polycomb 
proteins and transcription activators and repressors and regulate epigenetic marks 
and transcription (Cho, Kim et al. 2006, Boultwood, Perry et al. 2010, Scheuermann, 
de Ayala Alonso et al. 2010). ASXL1 is important for normal and myeloid 
differentiation. Both ASXL1 and ASXL2 are essential for the anteroposterior 
patterning of the mesoderm and homeotic transformation of the axial skeleton. 
ASXL1 and its paralog ASXL2 play an important role in the regulation of peroxisome 
proliferator-activated receptors (PPARs) and play opposite roles in adipocyte 
differentiation. ASXL2 promotes adipocyte differentiation whereas ASXL1 blocks in 
mouse 3T3-L1 cells (Park, Yoon et al. 2011). It was reported that loss or deletion of 
ASXL1 in osteoblasts and their progenitors leads to dramatic bone loss and 
decreased a number of bone marrow stromal cells (BMSCs) (Zhang, Xing et al. 
2016). 
1.6.3 ASXL1 and interacting proteins 
ASXL proteins are known to be the members of Enhancer of Trithorax and Polycomb 
(ETP) group proteins and are activators and repressors of gene transcription, 
depending on their interacting partners and cellular context. ASXL1 along with BAP1 
is a part of the Polycomb repressive deubiquitinase complex (PR-DUB) which 
deubiquitinates monoubiquitinated H2AK119 mark generated by PRC1 complex and 
is an important Polycomb Repressor group protein, responsible for repressing genes 
controlling cell differentiation. Both ASXL1 & 2 regulate the de-ubiquitinating activity 
of BAP1 (Scheuermann, de Ayala Alonso et al. 2010, Sahtoe, van Dijk et al. 2016). 





(PRC2), such as SUZ12 and EZH2, which increases the repressive mark, histone 
H3K27 methylation. Inhibition or loss of ASXL1 function leads to a decrease in 
H3K27me3 levels (Lee, Cho et al. 2010, Sugimoto, Muramatsu et al. 2010). ASXL1 
also interacts with HP1α/CBX5, a component of the heterochromatin repressive 
complex through PxVxL motif and regulates the activity of LSD1 (Lysine-Specific 
Demethylase 1) (Lee, Cho et al. 2010, Beisel and Paro 2011). Apart from BAP1, 
ASXL1 is also known to interact with the UTX (Ubiquitously Transcribed 
Tetratricopeptide Repeat, X chromosome) and LSD1, histone demethylases as well 
as the MLL (Mixed-Lineage Leukemia) and EZH2 (Enhancer of Zeste Homologue 2) 
histone methyltransferases (Gelsi-Boyer, Brecqueville et al. 2012). 
1.6.4 ASXL1 in cancer 
Mutations of ASXL1 are associated with several cancers. ASXL family members 
have dual functions, as they act either as tumor suppressors or as oncogenes in a 
context-dependent manner. Truncation mutations in the ASXL1 gene are frequently 
observed in myeloid malignancies, whereas amplification, translocation or point 
mutations of the ASXL1 gene have been observed in other types of human cancers 
(Gelsi-Boyer, Trouplin et al. 2009).  Nonsense point mutations or frame-shift 
mutations of ASXL1 occur in hematological malignancies such as myelodysplastic 
syndrome (MDS), myeloproliferative neoplasms (MPN), acute myeloid leukemia 
(AML) and chronic lymphocytic leukemia (CLL) (Carbuccia, Murati et al. 2009, Gelsi-
Boyer, Trouplin et al. 2009, Quesada, Conde et al. 2012). ASXL1 mutations lead to 
aggressive disease and the patients have poor over survival rate. Whole-exome 
sequencing analyses revealed that ASXL1 is mutated in 2.9% of CLL cases 





mutated in 45.3% of CMML cases, 30% of secondary AML cases, 16.2% of MDS 
cases, 34.5% of MPN cases,  and 6.5% of de novo AML cases (Gelsi-Boyer, 
Brecqueville et al. 2012). ASXL1 is most frequently mutated in colorectal cancer 
(CRC) cell lines with microsatellite instability (MSI) (Williams, Bird et al. 2010). 
ASXL1 is also mutated in several other cancers such as castration-resistant prostate 
cancer, breast cancer, liver cancer and head and neck squamous cell carcinoma (Li, 
Zhao et al. 2011, Stransky, Egloff et al. 2011, Grasso, Wu et al. 2012).  ASXL1 is 
amplified and overexpressed in 5.1% of cervical cancers (Scotto, Narayan et al. 
2008). ASXL1 mutations are associated with adverse outcome in leukemia patients 
(Katoh 2013, Aumann and Abdel-Wahab 2014). Mutations in ASXL1 leads to 
depletion of ASXL1 protein or truncated protein expression. The truncated proteins 
lead to gain-of-function as they retain the N-terminal BAP1 interacting domain and 
leads to enhanced H2AK119Ub deubiquitinating activity.(Scheuermann, de Ayala 
Alonso et al. 2010, Balasubramani, Larjo et al. 2015)  
1.7 Aim of the project 
ASXL family members are known to be mutated in several cancers and their role in 
cancers was poorly characterized. Many reports showed that ASXL proteins have 
epigenetic regulatory functions by recognizing and replacing several histone 
modifications by interacting with demethylases, methyltransferases and 
deubiquitinases. In this study our aim is to elucidate the role of ASXL1 during tumor 
progression and metastasis, especially in epithelial-to-mesenchymal transition (EMT) 
and decipher its epigenetic mode of action. To understand the ASXL1 mediated 
effects on tumorigenesis, two approaches were followed. In our first approach, 





and breast cancer cells. In the other approach, RNA-seq and ChIP-seq analyses 






















2.1 Technical equipment 
EQUIPMENT COMPANY 
2100 Bioanalyzer Agilent Technology, Santa Clara, USA 
5100 Cryo 1°C Freezing Container  Thermo Fisher Scientific, Waltham, USA 
Agarose gel chamber Harnischmacher Labortechnik, Kassel  
Balance Sartorius AG, Goettingen  
Bandelin Sonoplus Sonicator Bandelin electr. GmbH & Co. KG, Berlin  
Biological Safety Cabinet “ Hera Safe ” Thermo Fisher Scientific, Waltham, USA  
Bioruptor® Plus Sonicator Diagenode SA, Liege, Belgium 
C1000™ Thermal Cycler Bio-Rad Laboratories GmbH, Muenchen  
Centrifuge (Megafuge 1.OR) Thermo Fisher Scientific, Waltham, USA 
Centrifuge 4°C (5417R) Eppendorf AG, Hamburg 
Centrifuge 4°C (Fesco 21) Thermo Fisher Scientific, Waltham, USA 
CFX96™ Optical Reaction Module  Bio-Rad Laboratories GmbH, Muenchen 
Confocal microscope LSM510 META  Leica, Germany 
Counting chamber (Neubauer)  Brand GmbH & Co. KG, Wertheim  
DynaMag™ 2 Life Technology, Carlsbad, USA 
DynaMag™ 96 side Life Technology, Carlsbad, USA 
Eclipse TS100 Nikon, Tokyo, Japan 
Electrophoresis & Electro transfer Unit  Bio-Rad Laboratories GmbH, Muenchen  
Freezer  -150°C (MDF-C2156VAN) Panasonic, Kadoma, Japan 
Freezer  -20°C Liebherr GmbH, Biberach  
Freezer -80°C “Hera freeze”  Thermo Fisher Scientific, Waltham, USA  
Gel Imager Gel iX Imager Intas Science Imaging GmbH, Goettingen 
HERA cell 150i CO2 Incubator Thermo Scientific, Waltham, USA 
Incubator (bacteria culture)  Infors AG, Bottmingen  
Incubator (bacteria)  Memmert GmbH & Co. KG, Schwabach  
Incubator (cell culture) “Hera cell 150“  Thermo Fisher Scientific, Waltham, USA  
Inverse Microscope “Axiovert 40 CFL”  Carl Zeiss MicroImaging GmbH, Goettingen  
Isotemp® water bath Thermo Fischer Scientific, Waltham, USA 
Magnet stirrer “MR3001”  Heidolph GmbH & Co. KG, Schwabach  
Microwave  Clatronic International GmbH, Kempen  





Mini-PROTEAN Tetra Cell Bio-Rad Laboratories, Hercules, USA 
Mr.Frosty® Cryo Freezer Thermo Fischer Scientific, Waltham, USA 
Nano Drop® ND-1000  Peqlab Biotechnology GmbH, Erlangen  
pH meter inoLab® WTW GmbH, Weilheim 
Pipette Aid® portable XP Drummond Scientific Co., Broomall, USA 
Pipettes “Research” Series Eppendorf AG, Hamburg 
Power supply “Power Pack P25T” Biometra GmbH, Goettingen 
PowerPac™ Basic Power Supply Bio-Rad Laboratories, Hercules, USA 
PowerPac™ HC Power Supply Bio-Rad Laboratories, Hercules, USA 
Qubit® 2.0 Fluorometer Invitrogen GmbH, Karlsruhe 
Refrigerator Liebherr GmbH, Biberach 
Repeat pipette Gilson Inc; Middleton, USA 
Scanner Epson V700 Photo Seiko Epson, Suwa, Japan 
ScanScope XT LMS Co., Ltd., Tokyo, Japan 
Shaker “Rocky” Schuett Labortechnik GmbH, Goettingen 
Table centrifuge (VWR Mini Star) VWR International, LLC, South Korea 
Test tube rotator Schuett Labortechnik GmbH, Goettingen 
Thermo mixer C Eppendorf AG, Wessling-Berzdorf 
Ultrapure Water System “Aquintus” Scientific Industries, Inc., Bohemia, USA 
Vacuum pump (BVC Control) Vacuubrand GmbH and Co. KG, Germany 
Vortex-Genie 2 Electro Scientific Industr. Inc; Portland, USA 
Water bath “TW 20” noLab® WTW GmbH, Weilheim 
X- Ray Cassettes Rego X-ray GmbH, Augsburg 
 
2.2 Consumable materials 
MATERIAL COMPANY 
96 Multiply® PCR plate white Sarstedt AG & Co., Nuembrecht 
96-well Multiplate PCR plate white 
(Pena-Llopis, Vega-Rubin-de-Celis et 
al.) Bio-Rad Laboratories GmbH, Muenchen 
Cell scraper (16 cm, 25 cm) Sarstedt AG & Co., Nuembrecht 
Cellstar 6- and 12-well cell culture plate Greiner Bio-One GmbH, Frickenhausen 
Cellstar PP-tube 15 and 50 ml Greiner Bio-One GmbH, Frickenhausen 





Cellstar tissue culture dish 145×20 mm Greiner Bio-One GmbH, Frickenhausen 
Cryo TubeTM Vial (1.8 ml) Thermo Fisher Scientific, Waltham, USA 
DNA loBind Tube (0.5 and 1.5 ml) Eppendorf AG, Wessling-Berzdorf 
Falcon® assay plate, 96 well VWR Int., LLC, West Chester, USA 
Gel blotting paper (Whatman paper) Sartorius AG, Goettingen 
Glass coverslips (18 mm) Gebr. Rettberg GmbH, Goettingen 
HybondTM-PVDF Transfer Membrane  GE Healthcare Europe GmbH, Muenchen 
Microtube 0,5 ml, 1.5 ml, 2 ml Sarstedt AG & Co., Nuembrecht 
Microtube 1.5 ml, conical VWR International GmbH, Darmstadt 
NORM-JECT Syringes of different 
volume Henke Sass Wolf GmbH, Tuttlingen 
Parafilm® “M” Pechiney Plastic Packaging, Chicago, 
USA 
PCR plate white (96-well Multiplate®) Bio-Rad Laboratories GmbH, Muenchen 
PET track-etched cell culture inserts BD Bioscience, Franklin Lakes, NJ, USA 
Petri dish 92×16 mm Sarstedt AG & Co., Nuembrecht 
Pipette filter tips Sartorius AG, Goettingen 
Pipette tips Greiner Bio-One GmbH, Frickenhausen 
Protan® Nitrocellulose transfer 
membrane Whatman GmbH, Dassel 
Shandon Coverplate Thermo Fisher Scientific, Waltham, USA 
Syringe filter, Ca-membrane Sartorius AG, Goettingen 
Tissue microarrays US Biomax,Inc., Rockville, MD, USA 
Ultralow attachment plates Corning Life sciences, NY, USA 




Acetic acid Carl Roth GmbH & Co. KG, Karlsruhe 
Adefodur WB developing concentrate Adefo-Chemie GmbH, Dietzenbach 
Adefodur WB fixing concentrate Adefo-Chemie GmbH, Dietzenbach 
Agar USB Corporation, Cleveland, USA 
Agarose Biozym Scientific GmbH, Oldendorf 
Agencount® AMPure® XP Beads Beckman Coulter Inc. Brea USA 





Ammonium persulfate (APS) Carl Roth GmbH & Co. KG, Karlsruhe 
Ammonium sulfate (NH4)2SO4 Carl Roth GmbH & Co. KG, Karlsruhe 
Ampicillin AppliChem GmbH, Darmstadt 
Aprotinin Carl Roth GmbH & Co. KG, Karlsruhe 
Bovine Serum Albumin (BSA) Carl Roth GmbH & Co. KG, Karlsruhe 
Bromophenol blue Sigma-Aldrich Co., St. Louis, USA 
Calcium Chloride (CaCl2) Carl Roth GmbH & Co. KG, Karlsruhe 
Chloroform Carl Roth GmbH & Co. KG, Karlsruhe 
Cholera Toxin Sigma-Aldrich Co., St. Louis, USA 
Colorless co-precipitant Bioline, Luckenwalde 
Co-precipitant Pink Sigma-Aldrich Co., St. Louis, USA 
Crystal violet Carl Roth GmbH & Co. KG, Karlsruhe 
DePeX mounting media VWR International GmbH 
Diethylpyrocarbonate (DEPC) Carl Roth GmbH & Co. KG, Karlsruhe 
Dimethyl sulfoxide (DMSO) AppliChem GmbH, Darmstadt 
di-Sodium hydrogen phosphate Carl Roth GmbH & Co. KG, Karlsruhe 
Dithiothreitol (DTT) GIBCO®, Invitrogen GmbH, Darmstadt 
DMEM GIBCO®, Invitrogen GmbH, Darmstadt 
DMEM/F12 Carl Roth GmbH & Co. KG, Karlsruhe 
dNTPs Th. Geyer GmbH & Co. KG, Renningen 
Epidermal Growth Factor (EGF) Carl Roth GmbH & Co. KG, Karlsruhe 
Ethanol absolute Carl Roth GmbH & Co. KG, Karlsruhe 
Ethidium bromide Sigma-Aldrich Co., St. Louis, USA 
Ethylene diamine tetraacetic acid (EDTA) Thermo Scientific HyClone, Logan, USA 
Fetal Bovine Serum (FBS) Sigma-Aldrich Co., St. Louis, USA 
Formaldehyde Carl Roth GmbH & Co. KG, Karlsruhe 
Glycerol Sigma-Aldrich Co., St. Louis, USA 
Glycine Carl Roth GmbH & Co. KG, Karlsruhe 
Horse Serum Sigma-Aldrich Co., St. Louis, USA 
Hydrochloric acid (HCl) Carl Roth GmbH & Co. KG, Karlsruhe 
Hydrocortisone Sigma-Aldrich Co., St. Louis, USA 
Immobilon™ Western HRP substrate Merck,Millipore KGaA, Darmstadt 
Insulin Sigma-Aldrich Co., St. Louis, USA 
Iodacetamide Sigma-Aldrich Co., St. Louis, USA 





Leupeptin Carl Roth GmbH & Co. KG, Karlsruhe 
Linear Acrylamide Thermo Fischer Scientific, Waltham, 
USA 
Lithium chloride (LiCl), 8M Sigma-Aldrich Co., St. Louis, USA 
Magnesium chloride (MgCl2) Carl Roth GmbH & Co. KG, Karlsruhe 
Methanol M. Baker B.V., Deventer, Netherlands 
Monopotassium phosphate Carl Roth GmbH & Co. KG, Karlsruhe 
N-ethylmaleimide (NEM) Sigma-Aldrich Co., St. Louis, USA 
Nickel chloride (NiCl2) Sigma-Aldrich Co., St. Louis, USA 
NonidetTM P40 (NP-40) Sigma-Aldrich Co., St. Louis, USA 
Opti-MEM GIBCO®, Invitrogen GmbH, Darmstadt 
PBS tablets GIBCO®, Invitrogen GmbH, Darmstadt 
Pefabloc SC Protease Inhibitor Carl Roth GmbH & Co. KG, Karlsruhe 
Penicillin-Streptomycin solution Sigma-Aldrich Co., St. Louis, USA 
Peptone Carl Roth GmbH & Co. KG, Karlsruhe 
Potassium acetate Carl Roth GmbH & Co. KG, Karlsruhe 
Potassium chloride (KCl) AppliChem GmbH, Darmstadt 
Potassium dihydrogen phosphate Carl Roth GmbH & Co. KG, Karlsruhe 
Protein-A Sepharose CL-4B GE Healthcare, Uppsala, Sweden 
Protein-G Sepharose 4 Fast Flow GE Healthcare, Uppsala, Sweden 
RNAiMAX New England Biolabs, Frankfurt am 
Main 
RNase inhibitor Invitrogen GmbH, Karlsruhe 
Roti®-Phenol Carl Roth GmbH & Co. KG, Karlsruhe 
Rotiphorese® Gel 30 Carl Roth GmbH & Co. KG, Karlsruhe 
Rotipuran® Chloroform Carl Roth GmbH & Co. KG, Karlsruhe 
Rotipuran® isoamylalcohol Carl Roth GmbH & Co. KG, Karlsruhe 
Sepharose™ CL-4B GE Healthcare, Uppsala, Sweden 
Skim milk powder Carl Roth GmbH & Co. KG, Karlsruhe 
Sodium acetate Carl Roth GmbH & Co. KG, Karlsruhe 
Sodium azide AppliChem GmbH, Darmstadt 
Sodium chloride (NaCl) Carl Roth GmbH & Co. KG, Karlsruhe 
Sodium deoxycholate AppliChem GmbH, Darmstadt 
Sodium dodecylsulfate (SDS) Carl Roth GmbH & Co. KG, Karlsruhe 





Sodium hydroxide (NaOH) Carl Roth GmbH & Co. KG, Karlsruhe 
Sodium pyruvate (Na-Pyr) USB Corporation, Cleveland, USA 
ß-Glycerolphosphate (BGP) Carl Roth GmbH & Co. KG, Karlsruhe 
SYBR Green I Carl Roth GmbH & Co. KG, Karlsruhe 
TEMED GIBCO®, Invitrogen GmbH, Darmstadt 
Tris Carl Roth GmbH & Co. KG, Karlsruhe 
Triton X-100 Carl Roth GmbH & Co. KG, Karlsruhe 
TRIzol® Reagent AppliChem GmbH, Darmstadt 
Trypsin-EDTA (0.05%) Invitrogen GmbH, Karlsruhe 
Tween-20 GIBCO®, Invitrogen GmbH, Darmstadt 
Xylene AppliChem GmbH, Darmstadt 
Yeast extract USB Corporation, Cleveland, USA 
α, α-Trehalose Dihydrate Carl Roth GmbH & Co. KG, Karlsruhe 
 
2.4 Kits and Reagents 
KIT and REAGENT COMPANY 
Agilent High Sensitivity DNA Kit Agilent Technology, Santa Clara, USA 
Bioanalyzer DNA High sensitivity kit Agilent Technology, Santa Clara, USA 
Immobilon Western Chemiluminescent 
HRP Substrate  Millipore, Billerica, USA 
ISOLATE II PCR and Gel Kit Bioline USA Inc; Taunton, USA 
LipofectamineTM 2000 Life technology, Carlsbad, USA 
LipofectamineTM RNAiMAX Life technology, Carlsbad, USA 
Microplex Library PreparationTM V2 Kit Diagenode SA, Liege, Belgium 
Microplex Library PreparationTM Kit Diagenode SA, Liege, Belgium 
NEBNEXT® UltraTM Library Prep Kit New England Biolabs, Ipswich, USA 
NucleoBond® Xtra Midi Macherey-Nagel Inc; Bethlehem, USA 
PageRulerTM Prestained Protein Ladder Fermentas GmbH, St. Leon--Rot 
QIAprep® Spin Miniprep Kit Qiagen GmbH, Hilden 
Qubit dsDNA HS assay Life technology, Carlsbad, USA 
SuperSigmal® West Femto Maximum Thermo Fisher Scientific, Waltham, 
USA 







2.5 Nucleic acids 
2.5.1 Vectors and expression constructs 
Name Reference 
pCMV6-Flag-ASXL1 (Abdel-Wahab, Adli et al. 2012)  
pSG5-HA-P2A-ERT2-Hygromycin This study 
pSG5-HA-P2A-ASXL1-Hygromycin This study 
 
2.5.2 siRNA Oligonucleotides 
For transfections, the individual siRNAs (- #4) against the respective genes were 
pooled in a 1:1:1:1 ratio. 
siRNA Target sequence 5’-3’ direction Source Cat. No. 
siASXL1#1 GAUCGUCAGUCCUUUCGUA Dharmacon D-012856-01 
siASXL1#2 GGAUUCAACUUUCACGUAU Dharmacon D-012856-02 
siASXL1#3 GCAGUGCACUAAAUAACGA Dharmacon D-012856-03 











2.5.3 Cloning primers 









2.5.4 RT PCR primers 





2.5.4.1 Quantitative PCR primers (qPCR) 
 Quantitative PCR primers were designed using the NCBI primer designing tool 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). 
Gene Name Primer Sequence (5’ – 3’) Reference 
ARID1B F GCAAGGTGTGAGTGGTTACTG This study 
ARID1B R GGACTGGGACGGCAGATACT This study 
ASXL1 F GGTCCTGTCTCAGTCCCTCA This study 
ASXL1 R ATAACCACGGGGTCAGAGGT This study 
CD24 F GCTCCTACCCACGCAGATTT This study 
CD24 R GAGACCACGAAGAGACTGGC This study 
CDH1 F CTTTGACGCCGAGAGCTACA This study 
CDH1 R AAATTCACTCTGCCCAGGACG This study 
CDH2 F GGGTCATCCCTCCAATCAAC This study 
CDH2 R ACCTGATCCTGACAAGCTCT This study 
DLL1 F GCAAGCGTGACACCAAGTG This study 
DLL1 R AAGTTGAACAGCCCGAGTCC This study 
FN1 F CCCTGGTGTCACAGAGGCTA This study 
FN1 R GAGAGAGAGCTTCTTGTCCTGTC This study 
HNRNPK F ATCCGCCCCTGAACGCCCAT (Karpiuk, Najafova 
et al. 2012) 
HNRNPK R ACATACCGCTCGGGGCCACT (Karpiuk, Najafova 
et al. 2012) 
PTEN F GTGGCGGAACTTGCAATCCT This study 
PTEN R CGGCTGAGGGAACTCAAAGT This study 
TJP3 F CAGAGCATGGAGGATCGTGG This study 
TJP3 R TCAGGTTCTGGAATGGCACG This study 
VIM F GGCTCGTCACCTTCGTGAAT This study 
VIM R CAGAGAAATCCTGCTCTCCTCG This study 
 
2.5.4.2 ChIP Primers  
Gene Name Primer Sequence (5’ – 3’) Reference 
PTEN TSS F AACCCTCCTAGGTCTCCTCG This study 





TJP3 TSS F GGCCGATTGACTGTTTCCAG This study 
TJP3 TSS R GTTCTGGGGTCCTGGGTC This study 
ARID1B TSS F GGGAGTAATGCGAGCGAAGT This study 
ARID1B TSS R TCCTCTCTAGCCCGGATATGG This study 
 
2.6 Proteins, enzymes and standards 
2.6.1 Antibodies 
2.6.1.1 Primary antibodies 
Primary antibodies for western blot, ChIP and immunofluorescence were used in the 
respective dilutions and concentrations. The antibody dilutions for immunoblot 
analysis were supplemented with 0.01% sodium azide. 
Antibody Source Cat. No. Clone WB IF ChIP 
ASXL1 Santacruz sc-98302 H-105 1:250  1 µg 
E-Cadherin Cell Signalling 3195 24E10 1:1000 1:200  
N-Cadherin Cell Signalling #13116 D4R1H 1:1000   
CD24 Hans Peter - SWA11 1:2   
Vimentin Santacruz sc-6260 V9 1:1000 1:200  
ZO-1 Cell Signalling 8193 D7D12 1:1000   
ZEB1 Sigma HPA027524 - 1:500   
BAP1 Santacruz sc-28383 C-4 1:500  1 µg 
AKT Cell Signalling 9272  1:1000   
P-AKT Cell Signalling 4060  1:1000   
H3K4me3 Diagenode - pAb-
003-050 
1:1000  1 µg 
H3K27me3 Diagenode - pAb-
195-050 
1:1000   
H2Aub1 Diagenode -
C15410002 
 1:1000   
H2Bub1 Hybridoma - 7B4 1:10   
H2B Cell Signalling 2934 53H3 1:5000   









Abcam Ab37415 -   1 µg 
WDR82 David G.Skalnik - - 1:500   
Cfp1 David G.Skalnik - - 1:250   
 
2.6.1.2 Secondary antibodies 
Antibody Source Cat. No. WB IF 
Goat Anti-Mouse IgG-HRP Santacruz sc-2005 
 
1:10,000  
Goat Anti-Rabbit IgG-HRP Santacruz sc-2004 
 
1:10,000  
Alexa Fluor®594 Goat Anti-
Mouse IgG 
Life Technologies A11005  1:500 
Alexa Fluor®488 Goat Anti-
Rabbit IgG 




Phusion Polymerase New England Biolabs, Frankfurt am Main 
Proteinase K Life Technology, Carlsbad, USA 
Restriction enzymes New England Biolabs, Frankfurt am Main 
T4 DNA Ligase New England Biolabs, Frankfurt am Main 
Reverse Transcriptase (M-MuLV) New England Biolabs, Frankfurt am Main 
RNase A Qiagen GmbH, Hilden 
Taq DNA Polymerase Prime Tech, Minsk, Belarus 
RNase Inhibitor New England Biolabs, Frankfurt am Main 
 
2.6.3 Molecular weight standards 
Standard Company 
Gene RulerTM DNA-Ladder Fermentas GmbH, St. Leon-Rot 






2.7 Buffers and Solutions 
2.7.1 ChIP Buffers 
Nelson Buffer (modified) 
Component Final concentration 
NaCl 150 mM 
EDTA (pH 8.0) 20 mM 
Tris (pH 7.5) 50 mM 
NP-40 (v/v) 0.5 % 
Triton-X-100 (v/v) 1 % 
NaF 20 mM 
 
Gomes Lysis Buffer 
 
Component Final concentration 
NaCl 150 mM 
NP-40 (v/v) 1 % 
Sodium deoxycholate 0.5 % 
Tris-HCl pH 8.0 50 mM 
EDTA 20 mM 




Weinmann Lysis Buffer 
 
Component Final concentration 
Tris-HCl pH 8.0 50 mM 
EDTA 10 mM 
SDS (w/v) 1 % 
 
Gomes Wash Buffer 
 





Tris-HCl pH 8 100 mM 
LiCl 500 mM 
NP-40 (v/v) 1 % 
Sodium deoxycholate (w/v) 1% 
EDTA 20 mM 




Component Final concentration 
Tris-HCl pH 8.0 10 mM 




Component Final concentration 









NiCl2 1 mM 1:1000 
Pefabloc 1 mM 1:100 
IAA 10 µM 1:10000 
BGP 10 mM 1:100 
NEM 1 mM 1:100 
Aprotinin/Leupeptin 1 ng/µl 1:1000 
 
2.7.2 Western blot Buffers 
SDS separating gel (X %) 
 
Acrylamide X % 





SDS (w/v) 0.1 % 
APS (v/v) 0.1 % 
TEMED 0.04 % 
 
SDS stacking gel (5 %) 
 
Acrylamide 5 % 
Tris-HCl pH 6.8 125.5 mM 
SDS (w/v) 0.1 % 
APS (v/v) 0.1 % 




Western salts (10X) (v/v) 10 % 
Methanol (v/v) 20 % 
 
Western salts (10X) 
 
Glycine 1.92 M 
Tris-HCl pH 8.3 250 mM 
SDS 0.02 % 
 
6X Laemmli buffer 
 
Tris-HCl pH 6.8 0.35 M 
Glycerol 30 % 
SDS (w/v) 10 % 
DTT 9.3% 
Bromophenol blue 0.02 % 
 
SDS Running Buffer 
 
Glycine 200 mM 





SDS (w/v) 0.1 % 
 
TBS 10X pH 7.6 
 
Tris-HCl 100 mM 








PBS 1 X 
NP-40 (v/v) 1 % 
Sodium deoxycholate 0.5 % 




TBST 1 X 








Pefabloc 1 mM 1:100 
BGP 10 mM 1:100 
NEM 1 mM 1:100 
Aprotinin/Leupeptin 1 ng/µl 1:1000 
 
10X PBS (pH 7.4) 
 
NaCl 730 mM 






*7H2O  14.3 mM 








Component Final concentration 
Tris-HCl pH 8.8 750 mM 
(NH4)2SO4 200 mM 
Tween-20 0.1 % 
 




MgCl2 3 mM 
SYBR Green 1:80,000 
dNTPs 0.2 mM 
Taq-polymerase 20 U/ml 
Triton X-100 0.25 % 




TAE buffer (50X) 
 
Tris 2 M 
Acetic acid 1 M 
EDTA  0.1 M 
 








LB medium     1X 




Peptone     1 % 
Yeast extract               0.5 % 
NaCl      86 mM 
 
DMEM cell culture medium 
 
DMEM phenol red medium 
Fetal bovine serum              10 % 
Penicillin     100 U/ml 
Streptomycin     100 μg/ml 
 
DMEM/F12 cell culture medium 
 
Phenol red-free high-glucose DMEM/F12 
Horse serum     5 % 
EGF      100 μg/ml 
Hydrocortisone    1 mg/ml 
Cholera toxin     1 mg/ml 
Insulin      10 mg/ml 
Penicillin     100 U/ml 
Streptomycin     100 μg/ml 
 
Cell freezing medium 
 
DMEM 42 % 
FBS 50 % 
DMSO 8 % 
 
PBS for cell culture 
 







2.9.1 Bacterial cells 
Escherichia coli DH10BTM from Invitrogen GmbH, Karlsruhe 
 
2.9.2 Human Cell lines 
Cell Line Species Tissue Origin Disease Source 
MCF10A Human Mammary 
gland/breast 
Nontumorigenic 




MCF12A Human Mammary 
gland/breast 
Nontumorigenic 








MCF10A with stable 
pSG5 
overexpression  
Human  Mammary 
gland/breast 
Nontumorigenic 
epithelial cell line 
This study 



















adenocarcinoma This study 
Co-IP Lysis Buffer 
 
Component Final concentration 
Tris-HCl pH 7.1 5 mM 
NaCl 25 mM 
Triton X-100 0.5 % 
NaF 25 mM 
Na3VO4 0.5 mM 



















Bio-Rad CFX Manager 3.1 
Bio-Rad Laboratories, Hercukes, USA 
Integrative Genome 
Viewer 2 https://www.broadinstitute.org/software/igv/download 
Gene Set Enrichment 
Analysis http://software.broadinstitute.org/gsea/index.jsp 
Image Lab Version 5.2 
build 14 Bio-Rad Laboratories, Hercukes, USA 












3.1 Cell culture 
3.1.1 Cell culture of mammary cells 
MCF10A and MCF12A (human breast epithelial) cells were cultured in phenol red-
free Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12) medium 
supplemented with 5% horse serum, 0.5 µg/ml hydrocortisone, 10 µg/ml Insulin, 20 
ng/ml human EGF (epithelial growth factor), 0.1 µg/ml Cholera toxin, 100 units/ml 
penicillin and 100 µg/ml streptomycin at 37°C under 5% CO2 atmosphere. MDA-MB-
231 (human breast cancer, adenocarcinoma) cells were cultured in high-glucose 
Dulbecco’s modified Eagles medium (DMEM) and GlutaMAX supplemented with 
10% fetal bovine serum (FBS), 100 units/ml penicillin and 100 µg/ml streptomycin at 
37°C under 5% CO2 atmosphere.  
3.1.2 Reverse-transfection with siRNA 
Reverse-siRNA transfections were performed using LipofectamineTM RNAiMAX 
according to the manufacturer’s instructions. For each 6-well transfection, 30 pmol of 
respective siRNAs were diluted with 500 µl of Opti-MEM and 5 µl of LipofectamineTM 
RNAiMAX was added and mixed gently. The transfection mixture was then 
incubated for 20 min at RT. Meanwhile, MCF10A, MCF12A or MDA-MB-231 cells 
were washed with 1XPBS, trypsinized and diluted in “respective normal medium” 
without antibiotics. Neubauer counting chamber was used to count the cells and 
nearly 250,000 cells (MCF10A or MCF12A) or 300,000 cells (MDA-MB-231) from the 
diluted cells were added to each 6-well containing the siRNA-LipofectamineTM 





containing antibiotics. Cells were harvested after 72 h. For transfections in 10 cm 
plates, four times more cell number and transfection reagents were used. 
3.1.3 Plasmid DNA transfection 
A day before transfection, cells were plated in 10 cm plates to attain approximately 
70-80% confluency on the day of transfection. The cells were washed twice with 
1XPBS and the medium was replaced with the respective antibiotic free medium. 
Plasmid transfection was performed using LipofectamineTM 2000 according to the 
manufacturer’s instructions. For each transfection, 8-10 µg of plasmid DNA was 
mixed with 2 ml of Opti-MEM in a reaction tube. In a second tube, 20 µl of 
LipofectamineTM 2000 was mixed with 2 ml of Opti-MEM and incubated for 5 min at 
RT. After combining the contents of both tubes and mixing gently by inverting, the 
samples were incubated for another 20 min at RT. The transfection mixture was then 
added to the respective plates containing cells and incubated for 4 h at 37°C. After 4 
h, the transfection medium was removed, the cells were washed with 1XPBS and 
fresh medium with antibiotics was added.   
3.1.4 Stable transfection with plasmid DNA  
To create a stable cell line MCF10A or MDA-MB-231 cells were transfected with 
respective linearized plasmid DNA (using VspI) as described in section 3.1.2. After 
transfection, cells were grown for 4 h in media without antibiotics and then the media 
was replaced with media containing antibiotics. Then the cells were trypsinized, 
diluted and transferred to new plates. The cells were grown in a selective media 
containing Hygromycin (100 µg/ml). The cells were grown in a selection medium for 





3.1.5 Migration assay 
To monitor the migration potential of the cells, a transwell migration assay was 
performed. The stable cell lines (MCF10A and MDA-MB-231 with stable ASXL1 
ectopic expression) or cells (MCF10A and MCF12A) transfected with respective 
siRNAs were used for this experiment. To study migration of the cells, 8.0 µm PET 
track-etched membrane cell culture inserts, pre-equilibrated with serum-free medium 
for at least 20-30 mins, were used. The cells were trypsinized and approximately 
50,000 MCF10A and MCF12A cells and 20,000 MDA-MB-231 cells were seeded into 
the cell culture inserts with normal culture medium and cells were allowed to migrate 
through the membrane. The cells were cultured for further 48 h and the cells were 
gently scraped from the upper side of the membrane using a Q-Tip. 100% methanol 
was used for the fixation of the migrated cells for 10 mins. Migrated cells were then 
stained using crystal violet staining (1% (w/v) crystal violet dissolved in 20% (v/v) 
ethanol) for 10 mins. The inserts were rinsed twice with distilled water to remove the 
excess staining and were allowed to dry. The crystal violet stained membrane with 
the migrated cells was visualized under the microscope and the images were taken 
using Nikon light microscope. 
3.1.6 Mammosphere formation assay 
In vitro proliferative capacity of the single-cell suspension was determined by 
mammosphere formation assay. In this method, single cells were grown in non-
differentiating and non-adherent conditions. The cell lines (stable cell lines or siRNA 
transfected) were trypsinized to form single-cell suspensions and were seeded at a 
density of nearly 2500 cells/ml in DMEM/F12 medium supplemented with 2% (v/v) 





basic fibroblast growth factor (bFGF) and 20 ng/ml human epidermal growth factor 
(EGF) were seeded into Corning® flat bottom ultra-low-attachment 96 well 
microplates (200 µl).  The cells were fed every 48 h by addition of fresh medium and 
grown for 6 days. The mammospheres formed were counted and images were taken 
using Nikon light microscope. Images were analyzed (used Celigo) and quantified 
and represented as “relative number of spheres”. The statistical significance of the 
triplicates was calculated. 
3.2 Molecular Biology  
3.2.1 Molecular cloning 
The ASXL1 construct used in this study was obtained by amplification of synthetic 
ASXL1 and cloning into pSG5–HA–P2A–ERT2–Hygromycin vector. 
3.2.1.1 Polymerase chain reaction (Scott, Korfi et al.) 
The pCMV6 plasmid with human ASXL1 (NM_015338) with an N-terminal FLAG tag 
was a generous gift from Dr. Ross L. Levine (Memorial Sloan-Kettering Cancer 
Center (MSKCC)) (Abdel-Wahab, Adli et al. 2012). This plasmid was used as a 
template for the amplification of hASXL1. The PCR reaction was set up as follows: 
10 µl of  5x Phusion High-Fidelity buffer, 100 ng of plasmid template, dNTPs mix to a 
final concentration of 200 µM, 5 µM of sense and 5 µM of antisense primers, 1 unit of 
Phusion® High-Fidelity DNA Polymerase and the total volume was made up to 50 µl 
by adding water.  









The final PCR product was analyzed on a 1% agarose gel with appropriate 
molecular weight markers and purified by using agarose gel purification kit (Bioline). 
3.2.1.2 Restriction enzyme digestion 
To clone hASXL1 into a pSG5 vector, restriction enzyme digestion was performed to 
cut the hASXL1 PCR product and the vector using NotI and SpeI. The restriction 
digestion mixture was set up as follows: 2-4 µg of DNA, 3 µl of 10x restriction 
enzyme buffer, 5 units of each restriction enzyme, made up with ddH2O to a total 
volume of 30 µl. The reaction was incubated at 37°C for overnight followed by heat 
inactivation of restriction enzymes at 95°C for 10 min. The digested PCR products or 
98 C – 3 min
2x
98 C – 30 sec
84 C – 30 sec
72 C – 4 min
2x
98 C – 30 sec 
82 C – 30 sec  
72 C – 4 min 
2x
98 C – 30 sec
80 C – 30 sec 
72 C – 4 min
20x
98 C – 30 sec
72 C – 4 min
72 C – 10 min
4 C (hold)
2x
98 C – 30 sec
78 C – 30 sec
72 C – 4 min 
2x
98 C – 30 sec
76 C – 30 sec
72 C – 4 min
2x
98 C – 30 sec 
74 C – 30 sec  





vectors were separated on a 1% agarose gel and subsequently gel eluted for further 
use. 
3.2.1.3 Agarose gel purification of DNA fragments 
DNA fragments of interest (amplified PCR products, digested PCR products and 
vector) were purified by electrophoresis on a 1% low melting agarose gel in 1x TAE. 
The samples were loaded along with molecular size markers to aid in excising out 
the right sized band of interest in a UV transilluminator. The DNA in the gel piece 
was isolated using agarose gel purification kit (Bioline). 
3.2.1.4 DNA ligation  
In order to ligate the hASXL1 insert into the pSG5-HA-ERT2-P2A-Hygromycin 
vector, the ligation mixture was set up as follows: 100 ng of restriction enzyme 
digested vector DNA, 300 ng of restriction enzyme digested insert DNA (ratio vector: 
insert, approximately 1:3), 2 μl of 10x ligase buffer, 400 U of T4 DNA ligase and 
reaction volume was made up to 20 μl with ddH2O. The ligation reaction was 
performed at 16°C overnight.  
3.2.1.5 Heat shock transformation  
For transformation, the competent bacterial (DH5α) cells were thawed on ice and 
incubated with DNA or ligation mixture on ice for 20-30 min with occasional mixing. 
After incubation, the cells were applied with heat shock at 42°C for 90 sec followed 
by chilling on ice for 3-5 min. The cells then were supplemented with 1 ml of LB 
medium and incubated at 37°C for 1 h followed by centrifugation. The supernatant 
was discarded and the cell pellet was resuspended in 200 µl of LB medium, which 





were incubated at 37°C overnight in a bacterial incubator after which the colonies 
were picked for further screening. 
3.2.1.6 Screening of recombinant clones and plasmid isolation 
The bacterial colonies obtained in the above protocol were randomly picked and 
inoculated into 3 ml LB medium with ampicillin and grown to saturation. The culture 
was centrifuged at 12,000 rpm for one min at 4°C and the supernatant was 
discarded. The cell pellet was resuspended, lysed and neutralized using Macherey-
Nagel buffers. The contents were spun at 11,000 g for 10 min at 4°C and the 
supernatant containing the plasmid was transferred to a fresh microfuge tube. The 
nucleic acids were precipitated by adding an equal volume of isopropanol at room 
temperature for 20 min and stored at -80°C for at least an hour. The DNA was 
pelleted by centrifuging at 11,000 g for 10 min.at 4°C. The pellet was washed with 
70% alcohol, dried and resuspended in a minimum volume of autoclaved water. An 
aliquot of the DNA was then digested with suitable restriction enzymes to release the 
insert analyzed 1-1.5% agarose gel electrophoresis. The positive clones were further 
confirmed by DNA sequencing. The positive bacteria culture was used to inoculate 
100 ml of LB medium supplemented with Ampicillin and incubated with shaking at 
37°C overnight. On the next day, the cells were pelleted and the plasmid DNA was 
purified using the Pure Macherey-Nagel (MN) Plasmid Midiprep kit according to the 
manufacturer’s instructions. 
3.2.2 RNA isolation 
RNA was isolated from the cultured cells using QIAzol® reagent according to the 
manufacturer’s instructions.  Culture medium was aspirated and cells were washed 





well (6 well plates), scraped and collected into 1.5 ml tubes. 100 µl of chloroform was 
added to the samples, the tubes were then vortexed approximately 20 sec and 
centrifuged at 12,000g for 20 min at 4°C. The upper aqueous phase was collected 
into a fresh 1.5 ml tube and then samples were precipitated with isopropanol at -
80°C for 2 h. After 2 h the samples were centrifuged at 12,000g for 30 min at 4°C. 
The pellets formed were washed with 70% ethanol, dried and resuspended in 40 µl 
of DEPC water. RNA concentration was measured using a NanoDrop. The isolated 
RNA was used for cDNA synthesis or RNA-sequencing. 
3.2.3 cDNA synthesis 
For cDNA synthesis 1 µg of total RNA was mixed with 6 µl of a master mix 
containing 4 µl of 2.5 mM dNTP mix and 2 µl of 15 µM random primers. DEPC water 
was added to make the volume up to 16 µl. The mixture was then incubated at 70°C 
for 5 min followed by cooling on ice for few sec.  To this, 4 µl of reverse transcription 
master mix containing 2 µl of 10x reaction buffer, 10 units of RNAse inhibitor, 25 
units of reverse transcriptase M-MuLV and 1.625 µl of DEPC water was added to 
each sample. cDNA synthesis was performed at 42°C for 1 hour. Then the enzyme 
was inactivated at 95°C for 5 min. Finally, cDNA was diluted up to 50 µl with DEPC 
water. 
3.2.4 Quantitative real-time PCR 
Quantitative real-time PCR was performed with a final reaction volume of 25 µl. One 
µl of cDNA or ChIP DNA and 24 µl of master mix was used for each reaction.  Each 
24 µl of master mix contains 14 µl of the qRT-PCR mix, 1.5 µl of 5 µM primer mix 
(forward and reverse) and 8.5 µl of ddH2O. qRT-PCR mixture consists of 20 mM 





20, 0.5 U/reaction Taq DNA Polymerase. 0.25% Triton X-100, 1:80,000 SYBR Green 
I and 300 mM Trehalose.  
A two-step PCR reaction was performed using the following protocol. 
 
The PCR reaction was followed by a melting curve analysis from 60°C to 95°C with 
read every 0.5°C. 
 cDNA was quantified using a standard curve made from all cDNA samples. 
HNRNPK or 36B4 primers were used as an internal reference gene to normalize all 
qRT-PCR samples before the statistical analysis. The expression levels were 
represented as relative to the control samples and expressed as “relative mRNA 
expression”.  
A standard curve made from the ChIP input DNA was used for the quantification of 
ChIP and ChIP input samples. ChIP samples were normalized to their corresponding 
input samples and represented as “% of input”. 
3.2.5 Chromatin immunoprecipitation (ChIP) 
3.2.5.1 Cross-linking and sonication 
For ChIP experiments, cells were grown in either 10 cm or 15 cm plates. Protein-
DNA complexes in cells were cross-linked with 1% formaldehyde in 1XPBS for 20 
min (ASXL1 ChIP) or 10 min (histone modifications ChIP) at RT. 1.25 M glycine was 
95°C– 2 min
95°C– 15 sec





added in order to quench the formaldehyde and incubated for 5 min. Cells were 
washed twice with ice- cold 1XPBS and 1 ml of Nelson buffer containing protease 
inhibitor cocktail was added. Then the cells were scraped and collected into 1.5 ml 
tubes. The nuclear pellet was isolated by centrifugation at 12,000g for 1 min at 4°C 
and the supernatant was discarded. The nuclear pellet was washed with 1 ml of 
Nelson buffer and again centrifuged.  The final nuclear pellet was resuspended in 
200-250 µl of Gomes Lysis buffer and incubated on the rotor for 15 min at 4°C. 
Samples were then sonicated using Bioruptor® Pico (Diagenode) at high power with 
30 sec on/off pulse for 15-30 cycles. Sonicated samples were centrifuged at 12,000 
g at 8°C for 10 min.  
3.2.5.2 Shearing check 
To check the sonication efficiency of chromatin, the shearing check was performed 
before proceeding with a pre-clearing step. 10 µl of the sonicated chromatin sample 
was taken into a separate tube and 100 µl of Weinmann Lysis buffer (WB) and 1 µl 
of Proteinase-K (20 mg/ml) were added and incubated in a thermo-shaker at 65°C 
(800 rpm) overnight. Samples were then spun down and DNA was isolated by 
phenol/chloroform/isoamyl alcohol extraction as described below (for visualization 
pink precipitant was used). The isolated DNA pellet was dissolved in 15 µl of 10 mM 
Tris-HCl (pH 8) containing 100 µg/ml RNAse A and incubated for 1 h at 37°C (800 
rpm). Then the DNA was mixed with the loading dye and allowed to run on 1.5% 
agarose gel at 100 V followed by analysis on gel documentation. The shearing of 






3.2.5.3 Pre-clearing and immunoprecipitation 
For pre-clearing, 100 µl of 50% sepharose beads slurry was added to the chromatin 
extract and incubated on a rotor for 1 h at 4°C. The samples were centrifuged and 
the supernatant was transferred to a fresh tube. The samples were diluted using 
Gomes Lysis Buffer containing proteinase inhibitor cocktail. Chromatin samples were 
aliquoted and samples were either snap frozen in liquid nitrogen and stored in -80°C 
or proceeded for immunoprecipitation reaction.  10% of ChIP extract per 
corresponding ChIP sample was collected as input into a separate tube and snap 
frozen. For each immunoprecipitation reaction, 100 µl of chromatin extract was 
diluted to 500 µl with Gomes Lysis Buffer containing proteinase inhibitor cocktail and 
1-2 µg of respective antibody was added and incubated overnight on a rotor at 4°C. 
Chromatin complexes were pulled down by adding 30 µl of 50% Protein-A sepharose 
slurry and incubated for 2 h at 4°C. After 2 h, samples were centrifuged at 2000g for 
2 min at 4°C. The samples were washed with different ice-cold buffers as follows: 
twice with Gomes Lysis Buffer, twice with Gomes Wash Buffer, twice with Gomes 
Lysis Buffer and twice with TE buffer. The samples were mixed gently with the 
buffers during washings.  
3.2.5.4 DNA isolation 
Immunoprecipitated chromatin complexes and input samples were treated with 15 µl 
of RNAse A (10 µg) diluted in 10 mM Tris-HCl pH 8 (0.2 µg/ µl) and incubated at 
37°C for 30 min. Protein bound to DNA was removed by treating the samples with 1 
µl of Proteinase-K (20 mg/ml) and incubated at 65°C on a thermo-shaker overnight. 
The samples were centrifuged at 2,000g for 2 min at RT and supernatant was 





4 µl of colorless co-precipitant (Bioline). Subsequently, 200 µl of 
phenol/chloroform/isoamyl alcohol (25:24:1) was added, vortexed for 30 sec and 
centrifuged at a maximum speed at 37°C for 2 min. The aqueous phase was 
transferred to a fresh tube and back extraction was performed by adding 200 µl of 10 
mM Tris-HCl pH 8 + 0.4 M LiCl and vortexed for 30 sec. Samples were centrifuged at 
a full speed and the aqueous phase was collected and pooled with the first one. 
Precipitation was performed by adding 1 ml of 100% ethanol for 2 h at -80°C 
followed by centrifugation at 15,000g for 30 min at 4°C. DNA pellets were washed 
with 70% ethanol and centrifuged at 15,000g for 5 min. The pellets were dried and 
resuspended in 40 µl of water. 5 µl of ChIP DNA was aliquoted into a fresh tube and 
diluted for analysis by quantitative real-time PCR to check the efficiency of ChIP. The 
background (nonspecific) binding was determined by performing a ChIP with a non-
specific IgG antibody. ChIP samples were normalized to input DNA samples, and 
displayed as “% of input”. 
3.3 Protein biochemistry 
3.3.1 Whole cell extract preparation  
For total protein extraction, the cells were washed with 1XPBS and lysed in ice-cold 
RIPA buffer containing proteinase inhibitor cocktail (1 mM Pefabloc, 10 mM BGP, 1 
mM NEM and 1 ng/µl Aprotinin/Leupeptin). The extracts were then sonicated for 15 
cycles for 30 sec on/off pulse using a Bioruptor® Pico (Diagenode) at high power to 





3.3.2 SDS polyacrylamide gel electrophoresis 
After sonication, the protein samples were boiled with Laemmli Buffer for 10 min at 
95°C. The proteins were separated on sodium dodecyl sulfate (SDS) polyacrylamide 
gels (SDS-PAGE) (Laemmli 1970). The resolving and stacking gel were prepared as 
described in the Materials section. Polyacrylamide gels were run in SDS running 
buffer at 100 V till the dye front reached the bottom of the gel. 
3.3.3 Immunoblot analysis and detection 
The proteins resolved according to their molecular weight by SDS-PAGE were later 
detected by immunoblot  (Towbin, Staehelin et al. 1992) using specific antibodies 
against the protein of interest. Separated proteins were then transferred at 100 V to 
nitrocellulose membrane for 90 min. The membrane with transferred proteins was 
then incubated with blocking solution (5% skimmed milk in TBST) at room 
temperature for 1 h to block non-specific antibody binding. Then the membrane was 
incubated at 4°C for overnight with appropriate primary antibody diluted in blocking 
solution as described in the materials section. On the next day, membrane was 
washed thrice with TBST buffer and incubated for 1 h with horseradish peroxidase-
conjugated secondary antibody diluted in blocking solution at RT. Membrane was 
then washed thrice with TBST buffer and analyzed for HRP signals by using 
Enhanced chemiluminescence reagent and further exposed in western blot imager 
(Biorad) or on X-ray films  
3.3.4 Co-immunoprecipitation  
Cells were washed with 1XPBS and scraped in 1.0 ml of ice-cold Co-IP lysis buffer 





were sonicated and centrifuged at 10,000 rpm for 10 min at 4°C. The supernatant 
was then transferred to a fresh 1.5 ml tube and resonicated followed by 
centrifugation. The supernatant was transferred to a fresh tube and 100 μl was 
collected to use as input. An appropriate amount of supernatant was incubated with 
1-2 μg of antibody for overnight at 4°C on a rotator. The next day, 30 μl of 50% slurry 
of Protein A or G sepharose was added and incubated for 2 h on a rotator at 4°C. 
Beads were collected by centrifugation at 1000 rpm for 2 min, washed twice with 
lysis buffer and resuspended in 50–100 μl of lysis buffer. Beads were boiled in 6x 
Laemmli buffer, loaded on SDS-PAGE and proteins of interest were detected using 
specific antibodies. 
3.3.5 Immunofluorescence  
MCF10A cells were transfected with respective siRNAs and grown on chamber 
slides. The cells were washed with 1XPBS and then fixed with 4% paraformaldehyde 
(PFA) for 20 min at RT. Cells were washed thrice with 1x  PBS to remove the 
residual PFA and permeabilized using 0.1% Triton X-100 for 10 min. After washing 
thrice with1XPBS, cells were blocked with 3% BSA (bovine serum albumin) for 20 
min followed by overnight incubation with primary antibody diluted in 3% BSA. Next 
day, unbound antibody was washed away thrice with 1XPBS and incubated with 
Alexa-488 or Alexa-594 conjugated secondary antibodies diluted in 3% BSA. Cells 
were washed thrice with 1XPBS and the nuclei were stained with DAPI followed by 
1xPBS wash three times. The samples were mounted with coverslips using the 
mounting medium. Images were taken using Leica inverted-2 confocal microscope 





3.4 Next generation sequencing 
3.4.1 RNA sequencing 
RNA sequencing was performed in duplicates. RNA integrity was checked by 
visualizing the RNA bands on a 1% formaldehyde-agarose gel before proceeding for 
library preparation.  The RNA samples with proper integrity were used for library 
preparation. 
3.4.1.1 Library preparation 
RNA library preparation was performed using the NEBNext® UltraTM Library Prep 
according to the manufacturer’s instructions. 1 μg of total RNA was used for the 
downstream processing. From the total RNA, mRNA enrichment was performed 
using polyadenylated magnetic beads. The enriched mRNA was fragmented by 
incubating the samples at 94°C for 15 min in a thermocycler. Fragmented and 
primed mRNA was used for the first and the second strand cDNA synthesis. Double-
stranded cDNA was purified using Agencourt AMPure XP beads and afterward end 
repair reaction (single base overhangs at 5′ end) which was then followed by adaptor 
ligation (sequencing adaptor) and purification steps. Purified adaptor-ligated cDNA 
samples were PCR amplified by using universal primer for all samples and a specific 
index primer for each sample which later allows the separation of individual sample 
loaded on the same lane of the sequencer.  
3.4.2 Chromatin immunoprecipitation sequencing (ChIP-seq) 
After confirming the efficiency of chromatin immunoprecipitation by quantitative real-
time PCR, isolated ChIP DNA was used for sequencing. The concentration of 





Fluorometer before starting the library preparation. ChIP sequencing was performed 
in duplicates. 
3.4.2.1 Library preparation 
2-10 ng of ChIP DNA was used for the library preparation. DNA samples were 
resonicated to make fragments of 200-300 bp size using Bioruptor® Pico 
(Diagenode). Then fragmented DNA was used for the library preparation. Library 
preparation was performed using NEBNext Ultra DNA library preparation kit (New 
England Biolabs) for histone modifications and MicroplexTM Library preparation kit v2 
for ASXL1 from Diagenode® according to the manufacturer’s instructions. End prep 
reaction was set by adding end prep reaction buffer and end prep enzyme mix (total 
reaction volume 65 µl) to each sample and incubated at 20°C for 30 min and then at 
65°C for 30 min. Adaptor ligation reaction was set up by adding following reagents to 
the samples: Blunt/TA ligase master mix (15 µl), ligation enhancer (1 µl), NEBNext 
adaptor for Illumina (2.5 µl) making the reaction volume to 83.5 µl. Then the samples 
were incubated at 20°C in a thermocycler for 15 min. 3 µl of USER enzyme was 
added to the samples and incubated at 37°C for 15 min. 0.9x AMPure XP magnetic 
beads were added to the adaptor-ligated DNA for size selection followed by two 
washes using 80% ethanol. Beads were dried and resuspended in 28 µl of 10 mM 
Tris-HCl pH 8.0. 23 µl of purified adaptor ligated DNA was PCR amplified by using 
specific index primers (barcode) for each library, which later allows the separation of 
individual sample loaded on the same lane of the sequencer. PCR amplified DNA 
was cleaned using AMPure XP beads and the DNA was resuspended in 33 µl of 10 





Each ChIP library DNA concentration was measured using Qubit® 2.0 Fluorometer 
and the fragment size of the libraries were analyzed using Agilent Bioanalyzer 2100 
(High Sensitivity DNA assay). ChIP DNA libraries were pooled together to a final 
concentration of 10 nM and then diluted to 2 nM. The pooled libraries were 
sequenced using HiSeq 2500 (Illumina) sequencer at the Transcriptome Analysis 
Laboratory (TAL), Göttingen.  
3.5 Bioinformatic analysis of RNA and ChIP sequencing data 
3.5.1 RNA-sequencing data analysis 
RNA sequencing raw data was obtained as Fastq files and the quality was checked 
using the FastQC tool on Galaxy. Then the Fastq files were then mapped to the 
human genome (hg 19) using the TopHat tool (settings were set to ‘very sensitive) 
(Kim, Pertea et al. 2013).  SortSam (version 1.126.0) was used to sort the 
coordinates from Picard tools on Galaxy. The resulted files were then used for read 
counting using the HTSeq tool (version 0.6.0) (Anders, Pyl et al. 2015). The output 
htseqcount files were used for DEseq package in R-script (Bioconductor version 3.2) 
(Love, Huber et al. 2014). The list of differentially regulated genes was used for 
Gene Set Enrichment Analysis (GSEA). GSEA was performed with standard 
parameters (1000 permutations of gene sets, Signal2Noise ranking metric) and 
significantly enriched pathways (c5.all gene sets) were selected (Subramanian, 
Tamayo et al. 2005). Gene Ontology (GO) analysis was performed using the DAVID 
(Database for Annotation, Visualization, and Integrated Discovery) software. DAVID 
is a web-based program for analyzing the list of genes associated with the biological 





3.5.2 ChIP-sequencing data analysis 
Raw ChIP sequencing data was obtained as Fastq files. The quality of the raw data 
was checked by running Fastq quality check (FastQC) tool on Galaxy (S.Andrews 
Babraham Institute).  After checking the quality of the raw data, the data was further 
analyzed using publicly available servers (Galaxy, Galaxy/Cistome and 
Galaxy/deepTools). 
3.5.3 Mapping and Peak calling 
The Fastq files were mapped to the human genome (hg 19, GRch37) ((Langmead 
and Salzberg 2012) using Bowtie2 tool on Galaxy, which involves alignment of short 
DNA reads to the human genome. The end result of the Bowtie2 was in SAM 
(Sequence Alignment Map) format which was then converted to BAM (Binary 
Alignment Map) format using SAM-to-BAM conversion tool (Li, Handsaker et al. 
2009). BAM files were then used for Model- Based Analysis of ChIP-seq 2 (MACS2) 
tool (Zhang, Liu et al. 2008), which helps in the identification of the peaks for the 
protein binding, commonly referred as peak calling with p-values ≤ 10e-5 and 
minimum FDR (q-value) cutoff for peak detection was set to 0.05.    
3.5.4 Normalization and visualization of ChIP- sequencing data 
The generated Bed file containing the peak location and Wiggle (Wig) file containing 
signal profile was further used to analyze the genome-wide enrichment of proteins or 
histone modifications. The total number of mapped reads were then normalized 
using the reads per kilobase per million (RPKM) option. Bigwig file was used to 
visualize the enrichment at the individual genomic regions using Integrative 





regulatory Element Annotation System (CEAS) was used to determine the 
enrichment of the ChIP regions at specific genomic locations compared to the whole 
genome (Shin, Liu et al. 2009). Bigwig files were used to generate aggregate profile 






In this study, the role of Additional Sex Combs Like 1 (ASXL1) in Epithelial-to-
mesenchymal transition (EMT) was examined. Our main goal was to reveal the 
potential role of ASXL1 as a tumor suppressor and understand the molecular 
mechanism involved in suppressing the stem cell phenotype in mammary epithelial 
and breast cancer cells. Cellular events such as cell migration, adhesion, invasion 
and stemness are essential for normal cells. Previous studies reported that ASXL1 is 
perturbed in different cancers but the mechanistic role of ASXL1 as a tumor 
suppressor and EMT suppression is not yet studied. We also focused on studying 
the epigenetic regulation of ASXL1 in EMT which is a potent driver for cancer 
progression and metastasis. For this we used cell lines derived from human breast 
tissue such as MCF10A, MCF12A and MDA-MB-231.  MCF10A and MCF12A are 
normal mammary epithelial cells and MDA-MB-231 is breast cancer cells and they all 
were used as a model system to study EMT. 
4.1 Role of ASXL1 in breast cancer  
4.1.1 Expression of ASXL1 is downregulated in breast cancer 
In order to demonstrate the functional role of ASXL1, we compared the expression of 
ASXL1 mRNA between normal and cancer tissues.  For this purpose, we used 
publicly available ‘Oncomine’ database. The Oncomine database contains a huge 
collection of gene expression datasets for a wide range of cancers, which allows the 
users to examine the expression of individual genes in context to different cancers 
and also in comparison with normal tissues. Breast carcinoma datasets were utilized 





were significantly downregulated in breast carcinoma compared to the normal breast 
tissues in four independent datasets (Fig. 6). Reduced levels of ASXL1 expression in 
breast cancer samples further supports the tumor suppressor role of ASXL1 in 
breast cancer. 
 
Figure. 6: ASXL1 gene expression in breast carcinoma. Expression of ASXL1 in breast 
cancer samples was found to be significantly downregulated when compared to the normal 
breast samples as depicted in four independent datasets. Publicly available Oncomine 
database was used to generate the above data. 
4.1.2 ASXL1 expression and survival analysis  
To investigate whether expression of ASXL1 can be used as a prognostic marker for 
































































































































Meier Plotter was used to elucidate the prognostic role of ASXL1 in breast cancer. 
The Kaplan-Meier plotter is a publicly available online software, which can be used 
to assess the effect of genes on survival using several cancer samples. Kaplan-
Meier relapse-free survival for all breast cancer patients was analyzed and we 
observed that breast cancer patients with low ASXL1 expression levels have poor 
relapse-free survival (RFS) compared to patients with high ASXL1 (Fig. 7). 
 
Figure. 7: ASXL1 expression level predicts the disease outcome. Kaplan - Meier plot for 
breast cancer showing that patients with low ASXL1 expression have significantly poor 
relapse-free survival rate compared to the patients with high ASXL1 expression. 
4.2 ASXL1 and epithelial-to-mesenchymal transition 
4.2.1 ASXL1 downregulation perturbs the expression of EMT pathway genes 
As a first step towards understanding the biological functions of ASXL1 in mammary 
epithelial cells, we performed siRNA-mediated downregulation of ASXL1 in MCF10A 
cells (non-transformed mammary epithelial cells). As ASXL1 expression was 
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transcriptome-wide analysis, MCF10A cells were transfected with either non-
targeting control siRNA or ASXL1 siRNA. After 72 h, total RNA was isolated and was 
used for mRNA sequencing.  A thorough analysis of differentially regulated genes 
was carried out, where the genes are initially sorted based on fold change and 
significance values. For further analyses the genes that are differentially perturbed, 
up regulated (FC ≥ 1.0) or down regulated (FC ≤ 0.65) with a padj ≤ 0.05 were 
selected.  
As assumed, a significant fraction of EMT regulated genes was affected by depletion 
of ASXL1 compared with control (ASXL1 vs Control). However, some genes are not 
affected by depletion of ASXL1, which implies that ASXL1 is not required for their 
regulation. Interestingly, a number of other genes were differentially regulated by 
ASXL1 loss.  To understand the mechanistic role of the ASXL1-regulated genes, we 
employed DAVID (Database for Annotation, Visualization, and Integrated Discovery), 
a web-based Gene ontology application. DAVID was used to determine the GO 
terms related to transcriptome-wide regulation and several biological pathways 
regulating important functions such as cell adhesion, motility were identified upon 
ASXL1 depletion (Fig. 8A). One of the primary and crucial characteristics of epithelial 
and differentiated cells in the tissues is to adhere to the extracellular matrix and to 
the adjacent cells. However, during metastasis, the altered cells eventually lose cell 
to cell and also cell to extracellular matrix contacts, enabling them to migrate to 
distant sites.  
To further understand the role of ASXL1-regulated genes, we employed GSEA 
(Gene Set Enrichment Analysis), which identifies the significantly enriched pathways, 





GSEA analysis, we could identify significantly enriched pathways associated with 
EMT and epithelial differentiation pathways in control conditions compared to ASXL1 
depletion (Fig. 8B). GSEA analysis suggests that the ASXL1 loss results in an EMT-
like phenotype, which may lead to metastasis. Furthermore, it also revealed an 
enrichment of gene signatures associated with a mammary stem cell phenotype and 
EMT pathways upon ASXL1 depletion. The graphical representation (enrichment 
plots) of pathways for epithelial differentiation and EMT identified from GSEA were 
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Figure. 8: ASXL1 regulate EMT and metastasis properties. (A) The upregulated and 
downregulated genes were used for DAVID Gene Ontology analysis. The significantly 
enriched biological pathways involved in cell migration and adhesion. (B and C) GSEA 
analysis recognizes EMT and epithelial differentiation pathways.  
KOBAYASHI_EGFR_SIGNALING
_24HR_UP


















































































































































































































































































































































































4.2.2 Loss of ASXL1 enhances EMT phenotype 
To elucidate the effect of ASXL1 expression on EMT phenotype, we performed 
several cell culture based assays in MCF10A and MCF12A cells. During EMT, 
epithelial cells lose their epithelial markers like E-cadherin and junction proteins and 
express mesenchymal markers like fibronectin, Vimentin and N-cadherin. This leads 
the cells to undergo morphological changes, lose cell-cell adhesion properties and 
become elongated. ASXL1 knockdown in MCF10A using siASXL1 transfection 
resulted in mesenchymal-like sporadic long spindle phenotype compared to si-
control transfected cells with intact ASXL1 (Fig. 9A).  Based on RNA-seq data, 
several epithelial and mesenchymal genes involved in EMT were selected for further 
validation. For this, gene expression analysis for EMT markers was performed by 
qRT-PCR and the results were depicted as “relative mRNA expression”. As 
expected, the epithelial markers (CDH1, TJP3) were significantly down-regulated 
while the mesenchymal markers (CDH2, VIM, FN1) were significantly upregulated in 
ASXL1 depleted cells compared to siControl transfected cells. We also checked the 
expression of CD24, a marker associated with a differentiated phenotype, which was 
reported to be absent in cancer stem-like cells (Al-Hajj, Wicha et al. 2003)  (Ponti, 
Costa et al. 2005). In support of the other data, CD24 expression was significantly 
decreased upon ASXL1 depletion. Furthermore, DLL1, a ligand for Notch signaling 
was significantly up-regulated in ASXL1 depleted cells (Fig. 9B & C).  These results 
suggest that ASXL1 is required for the expression of epithelial genes and for 

















































































































































































































Figure. 9: Depletion of ASXL1 induces EMT phenotype. (A) Phase contrast images 
exhibiting the morphological changes of MCF10A cells upon ASXL1 knockdown. Scale bars 
are represented as 100 µm. (B)  Gene expression levels of epithelial markers (CDH1 and 
TJP3) and mesenchymal markers (CDH2, FN1 and VIM) were analyzed by qRT-PCR in (B) 
MCF10A and (C) MCF12A cells and represented as “relative mRNA expression” normalized 
to HNRNPK expression level. Data are shown as mean ± SD. n=3. ***p ≤ 0.005, **p ≤ 0.01, *p 
≤ 0.05. 
We also checked the expression of EMT markers by Western blot following the 
depletion of ASXL1 in MCF10A and MCF12A cells. Consistent with our gene 
expression analysis, ASXL1 depletion resulted in upregulation of mesenchymal 
markers, Vimentin, N-cadherin and ZEB1 and downregulation of epithelial markers, 
E-cadherin and ZO1 (Fig. 10A). To further support the findings of EMT marker’s 
gene expression at RNA and protein level in ASXL1 depleted cells, we visualized 
selected EMT markers, by immunofluorescence staining and confocal microscopy. 
For this, we used MCF10A cells transfected with siControl and siASXL1 and stained 









































































































































































































Vimentin 72 h post transfection. Confocal analyses of the immunofluorescence 
staining revealed a significant downregulation of the epithelial marker, E-cadherin 
and a strong upregulation of the mesenchymal marker, Vimentin in ASXL1 depleted 





















Figure. 10: ASXL1 loss enhances EMT phenotype. (A) Immunoblotting analysis of whole 
cell lysates depicting decreased expression of epithelial markers (E-cadherin and ZO1) and 
increased expression of mesenchymal markers (N-cadherin, Vimentin and ZEB1) upon loss 
of ASXL1 in MCF10A and MCF12A cells. ASXL1 immunoblot shows the knockdown 
efficiency. HSC70 was used as a loading control. (B) Immunofluorescence staining of 
































indicates enhanced EMT. DAPI was used to stain the nuclei. Scale bars are represented as 
50 µm.  
4.2.3 ASXL1 depletion enhances migratory properties 
In cancer cells, acquiring EMT phenotype is the foremost step for migration which 
helps to transform differentiated cells into the stem-cell-like state (Mani, Guo et al. 
2008) (Polyak and Weinberg 2009). One of the main features of EMT is to increase 
the migratory potential of cells to travel to distant places to develop a secondary 
tumor (metastasis). The earlier results revealed that the loss of ASXL1 enhances 
EMT-like phenotype. To understand whether this in turn enhances the migratory 
potential of the cells, we performed a transwell migratory assays in MCF10A and 
MCF12A cells. For this, the cells were transfected with either control or ASXL1 
siRNAs and grown for 48 hours. After 48 hours, cells were seeded into 8.0 µm PET 
track-etched membrane cell inserts and allowed to migrate through the membrane 
for further 48 hours. Finally, the migrated cells on the membrane were visualized by 
crystal violet staining, which revealed that ASXL1 depletion leads to enhanced 
migratory potential compared to the control cells (Fig. 11). Together, these findings 






Figure. 11: Loss of ASXL1 promotes migratory potential. MCF10A and MCF12A cells 
were used for the transwell migration assay. Cells transfected with siASXL1 and siControl 
were seeded as single cells (50,000) into the upper Chamber of the insert after 48 hours. 
Cells are allowed to migrate for additional 48hrs and fixed with 100% methanol. The 
membrane was stained by using crystal violet. There is an increased migration in ASXL1 
depleted in MCF10A and MCF12A cells. Scale bars are represented as 100 µm. 
4.2.4 Loss of ASXL1 induces stem cell characteristics 
In order to identify the enrichment of stem cell populations in vitro, the 
mammospheres culture in breast cancer has been widely used (Grimshaw, Cooper 
et al. 2008). The cells transfected with Control and ASXL1 siRNAs were seeded as 
single cells into low attachment plates and allowed to grow in non-adherent and non-
differentiating conditions. Therefore, single cells possessing stem cell properties 
could give rise to 3D spheres called mammospheres the number of which were later 
counted. ASXL1 depletion significantly increased the formation of the number of 
mammospheres (Fig. 12A & B) which suggests an important role of ASXL1 in 
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Figure. 12: ASXL1 depletion induces stem-cell properties. (A) Phase contrast images of 
mammospheres upon control and ASXL1 siRNAs transfection in MCF10A cells. 10x 
magnification. Scale bars are represented as 100 µm. (B) The mammospheres formed were 
quantified and represented as “relative number of mammospheres”. The data indicated that 
there is an increase in mammospheres number upon ASXL1 knockdown. The data are 
represented as ± SD. n=3. ***p ≤ 0.005, **p ≤ 0.01, *p ≤ 0.05. 
4.3 Genome-wide occupancy of ASXL1 
Our results demonstrated that ASXL1 plays an important role in suppressing EMT 
phenotype in normal breast epithelial cells, which was supported by our 
transcriptome-wide analysis. However, additional studies are needed to further 
understand and characterize the functional and mechanistic role of ASXL1 in EMT 
during tumor progression and metastasis.  Genome-wide occupancy studies were 
performed to understand the mechanism of action and determine the vital target 
genes of ASXL1. For this, we performed chromatin immunoprecipitation followed by 

















































4.3.1 Enrichment of ASXL1 on promoter regions 
ChIP-sequencing of ASXL1 was performed in MCF10A to investigate the occupancy 
of ASXL1 on specific genome locations like promoters, introns and coding exons 
using a tool, CEAS (Cis-regulatory Annotation System). CEAS is a part of Cistrome 
package which is used to determine the relative enrichment of ChIP-binding regions 
at specific genome regions with respect to the whole genome.  CEAS data pie chart 
depicts the distribution of ASXL1 enrichment in various genomic regions. CEAS 
analysis revealed that the majority of ASXL1 binding sites (70.2%) were confined to 
the distal intergenic regions compared to the whole genome (Fig. 13A & B). CEAS 
also revealed that a significant portion (8% and 9.5%, respectively) of ASXL1 binding 
sites were confined to promoter regions and introns compared to the whole genome.  
A small portion (4.8%) of binding sites was confined to coding exons. Furthermore, 
aggregate plot analysis was performed to observe the ASXL1 enrichment around the 
transcription start site (TSS) of the ASXL1 bound genes, which revealed that the 
highest ASXL1 enrichment near the TSS region of the genes and a low signal at the 
5kb upstream and downstream stream of the TSS (Fig. 13C). Taken together these 
results show that ASXL1 is mostly recruited to promoter and distal intergenic regions 
of target genes genome-wide. Furthermore, a very few ASXL1 binding sites were 










Promoter (<=1000 bp) 1.1 8
Promoter (1000-2000 bp) 0.7 1.4
Promoter (2000-3000 bp) 0.6 0.7
Downstream (<=1000 bp) 0.9 0.6
Downstream (1000-2000 bp) 0.7 0.7
Downstream (2000-3000 bp) 0.6 0.5
5'UTR 0.4 2.4
3'UTR 1.4 1.2
Coding exon 1.9 4.8
Intron 41.6 9.5
Distal intergenic 50 70.2
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Figure. 13: ASXL1 enrichment in the genome. (A) Pie chart depicting the relative 
occupancy of ASXL1 on various genomic regions with respect to the whole genome. (B)  
Percentage enrichment of ASXL1 enrichment regions around the promoter relative to the 
genome. (C) Aggregate plot showing average ASXL1 enrichment ±5 kb around the 
transcriptional start site (TSS). 
4.3.2 ASXL1 occupancy on individual genomic regions 
To examine the mechanistic role of ASXL1 in EMT, ChIP-seq analysis was 
performed in MCF10A cells. Genome-wide and single gene analyses show that 
ASXL1 largely occupies regions of the transcription start site (TSS). Remarkably, we 
observed a prominent ASXL1 peak around the promoter regions of ASXL1 affected 
genes (PTEN, TJP3 and ARID1B) (Fig. 14A). To confirm whether ASXL1 indeed 
directly bind to the above genes, we designed primers across the TSS, for ChIP-
qRT-PCR analysis, where the ASXL1 peak was visualized. And, ASXL1 ChIP was 
performed in MCF10A cells with or without ASXL1 depletion followed by the 
confirmation of ASXL1 enrichment using ChIP-qRT-PCR.  Consistent with the ChIP-
seq results, ChIP-qRT-PCR analysis of ChIP samples showed a significant 
enrichment of ASXL1 binding on the TSS region of PTEN, TJP3 and ARID1B genes. 
Average Profile of ASXL1 around the Centre of Sites























Furthermore, the ChIP-qRT-PCR analysis showed a significant decrease of ASXL1 
binding on the TSS upon ASXL1 depletion, which proves the specificity of ASXL1 




Figure. 14: ASXL1 enrichment on the promoters of single genes. (A) ChIP-seq profile of 
ASXL1 on PTEN, TJP3 and ARID1B genes. Significant peak was observed around the TSS. 
(B) ChIP analysis of ASXL1 enrichment on TSS of single genes in MCF10A cells with and 





























































“% of Input”. IgG antibody was used a negative control to measure the background signal 
level and displayed as a dotted line. Data are shown as mean ± SD. n=3. 
4.4 ASXL1 occupancy correlate with gene expression 
To determine whether ASXL1 play a direct role in regulating transcription of its target 
genes, the expression of these genes was studied in presence or absence of 
ASXL1. For this, MCF10A and MCF12A cells were transfected with siControl or 
siASXL1 followed by RNA isolation 72 h post transfection and cDNA preparation. 
This cDNA was used to assess the changes in expression of PTEN, TJP3 and 
ARID1B mRNA levels by qRT-PCR, which revealed that there was a significant 
decrease in gene expression of PTEN, TJP3 and ARID1B upon ASXL1 depletion in 
both MCF10A and MCF12A cells (Fig. 15A & B).  These results confirm that ASXL1 
























































































Figure. 15: ASXL1 directly regulates gene expression. Gene expression levels of ASXL1 
bound genes (PTEN, TJP3 and ARID1B) were analyzed by qRT-PCR in (A) MCF10A and 
(B) MCF12A cells and represented as “relative mRNA expression” normalized to HNRNPK 
expression level. The qRT-PCR reveals that there is a significant decrease in expression of 
genes in ASXL1 depleted cells. Data are shown as mean ± SD. n=3. ***p ≤ 0.005, **p ≤ 0.01, 
*p ≤ 0.05. 
4.5 Generation of ASXL1 expressing stable cell line  
To further validate the role of ASXL1 in EMT, MCF10A (normal breast epithelial 
cells) and MDA-MB231 (human breast cancer, adenocarcinoma) cells were stably 
transfected with   linearized expression vector for ASXL1 or control vector and grown 
in Hygromycin selection medium for a few weeks. These stable cells were utilized for 
further studies. 
4.5.1 Ectopic expression of ASXL1 reverses EMT phenotype 
To reveal the effect of ASXL1 expression on EMT phenotype, we performed several 
cell culture based assays in the stable cell lines expressing ASXL1. As already 
shown, ASXL1 depletion results in downregulation of epithelial markers and 
upregulation of mesenchymal markers. We then checked whether overexpression of 


















































































epithelial markers and decrease in the expression of mesenchymal markers in 
MCF10A and MDA-MB-231 cells.  For this, we isolated RNA and protein samples 
from the stable cell lines. The gene expression levels were analyzed by qRT-PCR 
and depicted as “relative mRNA expression”. The epithelial markers (CDH1, TJP3) 
were significantly up-regulated and mesenchymal markers (CDH2, VIM, FN1) were 
significantly down-regulated in ASXL1 expressing stable cells compared to the 
control cells. Furthermore, the genes bound by ASXL1 were also regulated by 









































































































































































































Figure. 16: Expression of ASXL1 induces MET phenotype. (A) Gene expression levels of 
epithelial markers (CDH1 and TJP3) and mesenchymal markers (CDH2, FN1 and VIM) were 
analyzed by qRT-PCR in (A) MCF10A and (B) MDA-MB-231 cells and represented as 
“relative mRNA expression” normalized to HNRNPK or 36B4 expression level. Data are 
shown as mean ± SD. n=3. ***p ≤ 0.005, **p ≤ 0.01, *p ≤ 0.05. 
To further support our findings from qRT-PCR data in the stable MCF10A and MDA-
MB-231 cells, the changes in EMT markers expression were analyzed by Western 
blot analysis. It was observed that epithelial markers, E-cadherin and ZO1 were 
upregulated and mesenchymal markers, Vimentin and N-cadherin were 
downregulated (Fig. 17). Altogether, these results demonstrate that ASXL1 









































































































































































































Figure. 17: ASXL1 expression reverses EMT phenotype. Immunoblotting analysis of 
whole cell lysates depicting increased expression of epithelial markers (E-cadherin and ZO1) 
and decreased expression of mesenchymal markers (N-cadherin, Vimentin and ZEB1) upon 
ectopic expression of ASXL1 in MCF10A and MDA-MB-231 cells. ASXL1 immunoblot shows 
the increase in ASXL1 expression. HSC70 was used as a loading control.  
4.5.2 ASXL1 expression reduces migratory properties 
From the earlier results, we demonstrated that ectopic expression of ASXL1 
reverses EMT-like phenotype whereas ASXL1 depletion promotes it. To understand 
whether an ectopic expression can inhibit the cell migration, as it is one of the 
important characteristics of EMT or metastasis, we performed transwell migratory 
assays in MCF10A and MDA-MB-231 cells, stably transfected with ASXL1 
expressing plasmid. For this the cells were trypsinized and 50,000 MCF10A and 
15,000 MDA-MB-231 cells each were seeded into 8.0 µm PET track-etched 
membrane cell inserts and allowed to migrate through the membrane for 48 hours. 
Visualization by crystal violet staining of the membrane revealed that ASXL1 
overexpression leads to a reduced migratory potential compared with the control 















Figure. 18: Expression of ASXL1 suppresses migratory potential. MCF10A and MDA-
MB-231 stable cells were used for the transwell migration assay. Stable cell lines, MCF10A 
(50,000) and MDA-MB-231 (15,000) were seeded as single cells into the upper Chamber of 
the insert. Cells are allowed to migrate for 48hrs and fixed with 100% methanol. The 
membrane was stained by using crystal violet. There is decreased migration in ASXL1 
overexpressed (A) MCF10A and (B) MDA-MB-231 cells. Scale bars are represented as 100 
µm. 
4.5.3 ASXL1 expression reduces stem cell characteristics 
To understand the role of ASXL1 on stem cell phenotype, the stable cell line, 
MCF10A was seeded as single cells into low attachment plates and allowed to grow 
in non-adherent and non-differentiating conditions. The mammospheres formed were 
counted and observed that the number of mammospheres were reduced upon 
ASXL1 overexpression which demonstrates that ASXL1 negatively regulates the 
mammospheres formation and anchorage-independent growth by suppressing the 
























Figure. 19: Expression of ASXL1 depletes stem-cell properties. (A) Phase contrast 
images of mammospheres upon control and ASXL1 expressing stable cells (MCF10A). The 
scale bars are represented as 100 µm. (B) The mammospheres formed were quantified and 
represented as “relative number of mammospheres”. The data indicated that there is a 
decrease in mammospheres number upon ASXL1 overexpression. The data are 
represented as ± SD. n=3. ***p ≤ 0.005, **p ≤ 0.01, *p ≤ 0.05. 
4.6 ASXL1 occupancy increased with ectopic ASXL1 expression 
To investigate the effect of ASXL1 expression on ASXL1 occupancy, ASXL1 ChIP 
was performed in MDA-MB-231 cells with ASXL1 stable expression. ASXL1 
enrichment was checked by ChIP-qRT-PCR, which showed a significant enrichment 
of ASXL1 occupancy on the TSS of TJP3, PTEN and ARID1B genes. Furthermore, 
the ChIP-qRT-PCR analysis showed a significant increase of ASXL1 binding on the 


















































Figure. 20: Enrichment of ASXL1 increased with ectopic ASXL1 expression. ChIP 
analysis of ASXL1 enrichment on the promoter of PTEN, TJP3 and ARID1B genes in MDA-
MB-231 stable cells with and without ectopic ASXL1 expression. Immunoprecipitated DNA is 
compared to input and represented as “% of Input”. IgG antibody was used a negative 
control to measure the background signal level and displayed as a dotted line. Data are 
shown as mean ± SD. n=3. 
4.7.1 ASXL1 regulates epithelial gene expression by promoting the expression 
of PTEN  
To further elucidate the mechanism by which ASXL1 promotes EMT, we examined 
the genes regulated following perturbation of ASXL1. We found that the expression 
of PTEN was significantly down-regulated by ASXL1 depletion and also up-regulated 
by ectopic expression of ASXL1. PTEN is a tumor suppressor and a multifunctional 
enzyme belonging to the phosphatase family which is reportedly mutated in several 
cancers and also known to regulate cell migration (Bowen, Doan et al. 2009, 





























































Figure. 21: PTEN expression and its effect on EMT markers. Gene expression levels of 
epithelial markers (CDH1 and TJP3) and mesenchymal markers (CDH2, FN1 and VIM) were 
analyzed by qRT-PCR in (A) MCF10A and (B) MDA-MB-231 stable cells and represented as 
“relative mRNA expression” normalized to HNRNPK expression level. Data are shown as 



















































































































































































































































































































































To elucidate the effect of PTEN on EMT phenotype, PTEN was depleted using 
siRNA in MCF10A and stable MDA-MB-231 cells followed by gene expression 
analysis of EMT markers using qRT-PCR. The epithelial markers, CDH1 and TJP3 
were downregulated and mesenchymal markers, CDH2, VIM, and FN1 were 
upregulated in PTEN depleted cells compared to siControl transfected cells. 
However, ASXL1 expression was not effected by PTEN depletion. Furthermore, the 
presence of ASXL1 ectopic expression in MDA-MB-231 cells was able to counteract 
the upregulation of mesenchymal markers, CDH2 and FN1, but not VIM (Fig. 21A 
and B). 
 To further support the role of PTEN in suppressing EMT, the changes in EMT 
markers were validated by Western blot analysis in PTEN depleted cells. As 
expected, mesenchymal markers, Vimentin and N-cadherin were upregulated and 
epithelial marker, E-cadherin was downregulated (Fig. 22). Taken together, our 







Figure. 22: ASXL1 loss enhances EMT phenotype. Immunoblotting analysis of whole cell 
lysates depicting decreased expression of the epithelial marker, E-cadherin and increased 
expression of mesenchymal markers, N-cadherin and Vimentin upon loss of PTEN in 
MCF10A and MDA-MB-231 stable cells. HSC70 was used as a loading control. 
4.7.2 PTEN regulates AKT activation 
PTEN is known to inhibit the PI3K–AKT signaling pathway by catalyzing 
phosphatidylinositol-3, 4, 5-trisphosphate (PIP3) to phosphatidylinositol-4, 5-
bisphosphate (PIP2) (Cully et.al, 2006). AKT signaling is associated with the 
epithelial-to-mesenchymal transition, epithelial differentiation, migration and 
metastasis (Larue and Bellacosa, 2005; Zhuang et al., 2012). To study whether 
PTEN depletion is associated with activation of the PI3K–AKT signaling pathway, an 
immunoblot for p-AKT was performed. In MCF10A cell lines, we observed an inverse 
correlation between PTEN expression and p-AKT levels. Furthermore, cells with 
depleted expression of ASXL1 and PTEN had increased p-AKT expression whereas 
cells with ASXL1 expression had decreased p-AKT expression (Fig. 23). With this, 
our results indicate that the depletion of ASXL1 and PTEN may lead to activation of 
PI3K-AKT pathway, which in turn promotes epithelial-to-mesenchymal transition. 













Figure. 23: PTEN depletion enhances AKT activation. Immunoblotting analysis of whole 
cell lysates depicting increased expression of p-AKT upon loss of ASXL1 and PTEN in 
MCF10A and decreased expression of p-AKT in ASXL1 expressing MDA-MB-231 stable 
cells. AKT was used as a loading control. 
 4.8 Depletion of ASXL1 regulates global levels of epigenomes 
Previously, it was shown that ASXL1 binds to the polycomb repressive complex 2 
(PRC2) members, specifically EZH2, EED, and SUZ12 and ASXL1 depletion inhibits 
trimethylation of H3K27 (H3K27me3). ASXL1 also associates with the H2A 
deubiquitinating enzyme BAP1 (Abdel-Wahab, Adli et al. 2012, Sahtoe, van Dijk et 
al. 2016). Thus, ASXL1 appears to be involved in both PRC2-mediated gene 
repression and counteracting PRC1 ubiquitination (Scheuermann, de Ayala Alonso 
et al. 2010, Abdel-Wahab, Adli et al. 2012, Chung, Schatoff et al. 2012, Dey, 
Seshasayee et al. 2012, Abdel-Wahab and Dey 2013). Furthermore, it was shown 
that H2Bub1 plays a tumor suppressor function and also reported to be decreased 
during tumor progression in breast cancer (Shema, Tirosh et al. 2008, Prenzel, 
Begus-Nahrmann et al. 2011). To understand epigenetic roles of ASXL1, we 
examined whether depletion of ASXL1 altered the global histone methylation and 
monoubiquitination levels in MCF10A cells. Western blot analysis showed decreased 
levels of global H3K4me3 and H2Bub1 and increased levels of H2Aub1 and no 
effect on H3K27me3 levels in ASXL1 depleted cells compared with control cells. 











These results indicate that ASXL1 is required to maintain H3 methylation and H2A 
monoubiquitination (Fig. 24). 
 
Figure. 24: ASXL1 depletion regulates histone methylation and monoubiquitination 
levels. ASXL1 depletion by siASXL1 decreases H2Bub1, H3K4me3 protein levels and 
increased H2AK119Ub protein levels. H2B was used as a loading control. 
4.9.1 ASXL1 enhances the gene expression by epigenetic regulation 
Methylation of lysine 4 on histone H3 (H3K4) at promoters is tightly linked to 
transcriptional regulation in human cells and also H3K4me3 is known to be an 
important histone modification coupled with transcription activation (Okitsu, Hsieh et 
al. 2010, Dong, Tsuji et al. 2015). In order to investigate the mechanisms by which 
ASXL1 regulates PTEN, ARID1B and TJP3 expression, we checked the average 
H3K4me3 signals (±5Kb) around the TSS region of ASXL1-bound genes genome-
wide in an aggregate plot for all the ASXL1-bound genes. And, we observed 
H3K4me3 enrichment across the ASXL1 bound peaks. Published ChIP-seq data for 














Figure. 25: H3K4me3 enrichment correlates with gene expression. Published H3K4me3 
ChIP-seq was used for the aggregate plot analysis on the ASXL1-bound peaks genome- 
wide. The analysis was performed around the (±5Kb) TSS of the genes. 
4.9.2 ASXL1 depletion leads to decreased H3K4me3 on ASXL1 bound genes 
To investigate the occupancy of H3K4me3 on ASXL1 bound genes, H3K4me3 ChIP-
seq data was used for the genome-wide and single gene analyses, which showed 
H3K4me3 enrichment around the transcription start site (TSS). Prominent peak was 
observed around the promoters of ASXL1 bound genes (PTEN and ARID1B) (Fig. 
26A). To confirm the enrichment of H3K4me3 on ASXL1 bound genes, we 
performed H3K4me3 ChIP in MCF10A cells with or without ASXl1 depletion and also 
in MDA-MB-231 cells with stable ASXL1 expression. The enrichment of H3K4me3 
was confirmed by ChIP-qRT-PCR. Consistent with the ChIP-seq results, qRT-PCR 
analysis of ChIP samples showed a significant enrichment of ASXL1 binding on the 
TSS region of ASXL1 bound (PTEN, TJP3 and ARID1B) genes. Furthermore, the 
qRT-PCR analysis showed a significant decrease of H3K4me3 enrichment on the 
TSS upon ASXL1 depletion whereas a significant increase of H3K4me3 enrichment 
on the TSS upon ASXl1 over-expression (Fig. 26B). Taken together, these results 
























confirm that ASXL1 promotes increased H3K4me3 occupancy on the genes and 







Figure. 26: H3K4me3 enrichment on the promoters of ASXL1 target genes. (A) ChIP-
seq profile of H3K4me3 on PTEN and ARID1B genes. Significant peak was observed 
around the TSS. (B) ChIP analysis of H3K4me3 enrichment on TSS of single genes in 
MCF10A cells with and without ASXL1 depletion and with and without ASXL1 
overexpression in MDA-MB-231 cells. Immunoprecipitated DNA is compared to input and 
represented as “% of Input”. IgG antibody was used a negative control to measure the 
background signal level and displayed as a dotted line. Data are shown as mean ± SD. n=3. 
4.9.3 ASXL1 cooperates with SET1 methylase complex to epigenetically 
enhance gene expression  
To further explain how ASXL1 positively regulates the H3K4me3 level at the 






































































































ASXL1 to check the interaction with SET1 complex and BAP1. SET1 complex 
methylate the histone 3 lysine 4 (H3K4) (Thornton, Westfield et al. 2014). Recently, 
BAP1 was shown to interact with and deubiquitinate the transcriptional regulator host 
cell factor 1 (HCF-1) which is one of the members of SET1 complex (Lee, Tate et al. 
2007, Narayanan, Ruyechan et al. 2007, Machida, Machida et al. 2009). We 
observed that ASXL1 physically interacts with H3K4-specific methyltransferase 
SET1 complex members (Cfp1 and Wdr82) and furthermore we also found that 
BAP1 also interacts with Wdr82 (Fig. 27)  
 
Figure. 27: ASXL1 and BAP1 associate with SET1 complex members. 
Immunoprecipitation followed by immunoblotting showed that ASXL1 interacts with Wdr82 
and Cpf1 whereas BAP1 interacts with only Wdr82. 
4.9.4 Depletion of ASXL1 leads to decreased expression of SET1 complex 
members 
 It was reported that the coactivator HCF-1 is required for recruitment of Setd1A and 
MLL1 and BAP1 is known to deubiquitinate HCF-1. From our Co-IP results, we found 
that ASXL1 and BAP1 were interacting with SET1 complex members. We performed 
immunoblotting to check the expression of Wdr82 and Cfp1 in ASXL1 depleted cells 
and also in ASXL1 overexpressing cells (Fig. 28). In ASXL1 depleted cells, we 
observed that Wdr82 expression was significantly decreased whereas Cfp1 









expression was partially decreased, which may affect the stability of SET1 complex 
and decreased methylation. In ASXL1 overexpressing cells there was increased 
Wdr82 expression whereas Cfp1 expression was not affected. Previously, it was 
shown that Wdr82 depletion leads to decreased Setd1A and Cfp1 expression (Lee 
and Skalnik 2008). Hence, Wdr82 is required for the targeting of Setd1A-mediated 
histone H3-Lys4 trimethylation near transcription start sites.  
 
Figure. 28: ASXL1 depletion regulates expression of SET1 complex members. The 















Breast cancer is the most frequently diagnosed cancer and the leading cause of 
cancer death in females and most of them are caused due to tumor invasion and 
metastasis. Genetic and epigenetic alterations in the normal cells lead to the 
formation of the malignant cells. The malignant cells lose control over the cellular 
processes including cell morphology, proliferation, migration, cell death and 
eventually forms a tumor. The cellular plasticity, the fundamental characteristic 
required by the cells during embryo development, plays an essential role in cancer 
development and metastasis, in which the epithelial tumor cells undergo enormous 
cellular modifications and transdifferentiate into mesenchymal cells by activating the 
epithelial-to-mesenchymal transition (EMT) process (Boyer and Thiery 1993, Hay 
1995, Vicente-Duenas, Gutierrez de Diego et al. 2009). In order to metastasize to 
distant sites, these cells reorganize their cytoskeleton, breakaway from tumor and 
migrate, invade and colonize to form secondary tumor by undergoing mesenchymal-
to-epithelial transition (MET) (Chambers, Groom et al. 2002, Bacac and Stamenkovic 
2008, Tsai and Yang 2013). Epigenetic processes play a vital role in the normal 
development and tissue-specific gene expression and its maintenance. However, the 
aberrant epigenetic state leads to an altered gene expression which can transform a 
normal cell into the malignant cell (Sharma, Kelly et al. 2010, Tam and Weinberg 
2013). ASXL1 is one among the frequently mutated genes in malignant myeloid 
diseases (Gelsi-Boyer, Brecqueville et al. 2012). ASXL1 was reported to be one of 
the components of various chromatin modifying complexes which regulate gene 
expression. (Abdel-Wahab, Adli et al. 2012). In this study, we focused on 





mechanism involved in ASXL1 mediated tumorigenesis and metastasis and to 
establish new therapeutic targets for preventing cancer progression and metastasis 
in various cancers.  
5.1 The role of ASXL1 as a potential tumor suppressor 
The development of cancer is a multistep and complex process and is initiated by 
the inactivation of tumor suppressor genes or the activation of oncogenes, which can 
eliminate the control on cell growth and proliferation and eventually transform a 
normal cell into a cancerous cell (Hahn and Weinberg 2002). Tumor suppressor 
genes function by keeping a constant check on cell proliferation and inducing 
apoptosis to maintain the tissue homeostasis, which is a native suppression of tumor 
formation. So, inactivation or loss of tumor suppressors results in loss of control over 
cell growth which is considered as one of the most important hallmarks of cancer 
development (Hanahan and Weinberg 2011). Based on the context-dependent 
functions of ASXL family members as transcription activators or repressors, these 
proteins are proposed to be tumor suppressive or oncogenic, which depends on the 
genes they activate or repress (Katoh 2013). ASXL1 is mutated in several types of 
cancers such as lung squamous and bladder cancer (Futreal, Coin et al. 2004, 
Kandoth, McLellan et al. 2013) ASXL1 is frequently mutated in myeloid malignancies 
and hematological cancers. ASXL1 mutations are associated with disease 
progression and poor clinical outcome (Abdel-Wahab, Adli et al. 2012, Valletta, 
Dolatshad et al. 2015, Wu, Bekker-Jensen et al. 2015). ASXL1 mutations are 
strongly associated with poorer survival in patients with myeloid malignancies (Shih, 





In our study, the examination of ASXL1 mRNA expression status in a wide spectrum 
of breast carcinoma datasets revealed the significant downregulation of ASXL1 
mRNA expression levels in breast cancer samples compared to the control samples. 
We have also tested the clinical utility of ASXL1 protein expression as a prognostic 
biomarker of breast cancer progression through examination of the association 
between ASXL1 and disease outcome. In our analysis, we found that the patients 
with low ASXL1 expression have significantly poorer relapse-free survival than the 
patients with high ASXL1 expression and collectively, there is an inverse correlation 
of ASXL1 expression with tumor malignancy. However, in-depth studies are needed 
to understand the role of ASXL1 in tumorigenesis completely.   
5.2 ASXL1 downregulation perturbs the global gene expression 
Depletion or inactivation of tumor suppressor genes leads to the reduced function of 
the gene. Loss of function leads to the increase in tumor cell number by increasing 
cell growth or by inhibiting cell death, which is caused due to the activation of genes 
regulating cell cycle or by suppressing the genes involved in apoptosis (Vogelstein 
and Kinzler 2004). As an initial step to understand the functional role of ASXL1 in 
breast cancer development and progression, the transcriptional effect of ASXL1 
depletion was obtained through mRNA expression profiling in normal breast 
epithelial cells, MCF10A. The transcriptome-wide sequencing analysis revealed that 
the expression of ASXL1 activates or suppresses a distinct set of genes which 
includes a small portion of genes involved in EMT process such as fibronectin, 
Vimentin, TJP-3, N-cadherin and E-cadherin and also stem cell marker, CD24. Other 
than EMT genes, a small subset of genes is also differentially expressed. PTEN, a 





cancers, including breast cancer and involved in tumorigenesis and progression 
(Zhang, Liang et al. 2013). ASXL1 depletion resulted in the perturbation of genes 
that are involved in cell adhesion, cell proliferation and cell motility. The putative 
tumor suppressor role of ASXL1 was confirmed by the GSEA and the DAVID 
functional annotation analyses. The gene Ontology analysis reveals that ASXL1 
controls cellular activities, that are exploited during cancer progression and 
metastasis, such as cell adhesion, cell proliferation, angiogenesis, cell death and cell 
motility. Furthermore, gene expression analyses of ASXL1 depleted MCF10A cells 
confirms that pathways related to breast cancer, epithelial differentiation, EMT and 
metastasis are among the top enriched pathways. This suggests that ASXL1 
depletion promotes EMT.  
5.3 The role of ASXL1 in cancer metastasis 
EMT and MET processes play an important role in the transition between epithelial 
and mesenchymal phenotype and are involved in the normal development and 
cancer metastasis. During the transition, the epithelial cells disrupt their intracellular 
tight junctions and cell-cell contacts and become mesenchymal cells. These cells 
acquire stem cell properties and enhance their invasive and migratory properties 
(Thiery and Sleeman 2006, Heerboth, Housman et al. 2015). Our analysis of global 
gene expression suggested the role of ASXL1 in EMT regulation and thus 
metastasis. To assess more and test further consequences, ASXL1 is either 
depleted or overexpressed.  
5.3.1 The role of ASXL1 in regulating EMT  
One of the important clues that have been obtained in this study is the possible 





development of the embryo and the formation of various tissues or organs. However, 
inappropriate activation of EMT in the normal cells leads to diseases, such as cancer 
by converting the epithelial cancer cells into stem-cell like mesenchymal cancer 
cells. In normal epithelial cells, the genes which make the cells in association with 
other cells in a tissue are expressed, however, the mesenchymal genes, which 
induce the cells to change morphology, and to breakaway for migration and invasion, 
are repressed. E-cadherin is involved in cell-cell adhesion and its loss is thought to 
be the initial step for enabling EMT and metastasis. In contrast, N-cadherin is 
elevated in EMT and can regulate cell-cell adhesion during the invasion. The switch 
of E-cadherin and N-cadherin expression induces EMT in several cancers, leading to 
enhanced cellular motility or invasion and decreased adhesion (Mani, Guo et al. 
2008, Onder, Gupta et al. 2008, Gupta, Onder et al. 2009).  
Our study reveals that depletion of ASXL1 induces a dramatic change in the 
morphology of MCF10A cells from epithelial to fibroblastic-like spindle-shaped 
phenotype. The alteration in cell morphology is one of the characteristics of EMT and 
is associated with changes in the expression of several genes. In our transcriptome-
wide analysis, we found that ASXL1 depletion significantly upregulates or 
downregulates some of the EMT-associated genes, which includes a reduced 
expression of epithelial markers such as E-cadherin and TJP3 and an increased 
expression of mesenchymal markers such as Vimentin, N-cadherin and fibronectin.  
To further determine the tumor suppressor role of ASXL1 in breast cancer, we 
evaluated the expression of ASXL1 in breast cancer cell line, MDA-MB-231 and 
observed that ASXL1 expression was downregulated. Furthermore, stable ASXL1 





marker expression and decreased mesenchymal marker expression. The epithelial 
marker, E-cadherin was decreased whereas the mesenchymal markers, Vimentin, 
and N-cadherin were increased in ASXL1 depleted cells.  In contrast, there is an 
increase in E-cadherin expression and a decrease in N-cadherin and Vimentin 
expression in the cells with ASXL1 overexpression. Immunofluorescent staining 
confirmed increased expression of Vimentin and reduced expression of E-cadherin 
in ASXL1 depleted MCF10A cells compared to the control cells, suggesting that 
these factors might contribute to induction of the EMT phenotype. The migration and 
invasion of cancer cells is an important process of cancer metastasis. Our studies 
using in vitro migration assays showed an increased migration potential of the 
normal mammary epithelial cell lines MCF10A and MCF12A upon ASXL1 depletion, 
whereas ASXL1 overexpression suppressed the migratory potential of the cells 
(MCF10A). More importantly, ASXL1 overexpression inhibited the migration of breast 
cancer cells (MDA-MB-231). Enhanced cell migration is a pronounced feature of 
advanced tumors (Friedl, Hegerfeldt et al. 2004) and therefore decreased ASXL1 
expression may potentially facilitate cancer progression.  
Furthermore, due to the inverse relationship between the expression of epithelial 
genes and mesenchymal genes, it seems that ASXL1, with its tumor suppressor 
function, may suppress the mesenchymal genes. Indeed, our data highlights the 
same that depletion of ASXL1 results in the upregulation of mesenchymal markers 
whereas overexpression results in repression of mesenchymal markers. Taken 
together, we have shown in this study that, upon depletion of ASXL1, mammary 
epithelial cells undergo a series of changes through which cells lose their epithelial 





5.3.2 ASXL1 expression regulates cancer stem cell pool 
Several reports have shown that breast cancer stem cells (BCSCs) have been 
implicated as the main driver for initiation, maintenance, progression and 
reoccurrence of breast cancer. Cancer stem cells (CSCs) are a small portion of 
undifferentiated malignant cancer cells within a tumor that have the capacity to self-
renew, proliferate and can differentiate/transdifferentiate into the heterogeneous 
population of cancer cells. (Clarke, Dick et al. 2006, Yao, Ping et al. 2011, Li, Yao et 
al. 2014, Liu and Fan 2015, Qiao, Liang et al. 2015). Recently, it was reported that 
EMT has been closely linked to the acquisition of CSCs-like characteristics such as 
enhanced self-renewal, CSC-gene expression and increased tumorigenicity (Mani, 
Guo et al. 2008, Sampieri and Fodde 2012). In our studies, we observed that the 
CSC marker, CD24 was downregulated in ASXL1 depleted mammary cells at both 
mRNA and protein level. Furthermore, ASXL1 depletion also increased the 
mammosphere formation which was suppressed by the overexpression of ASXL1 in 
MCF10A cells. Taken together, the results strongly suggest the role of ASXL1 in 
mammospheres formation and anchorage-independent growth by suppressing the 
stem cell phenotype.  
5.4 Genome-wide distribution of ASXL1 
From our transcriptome-wide data, we found the potential role of ASXL1 in regulating 
EMT. In order to gain mechanistic insight into the function of ASXL1 in EMT 
regulation, we need to understand ASXL1 mediated regulation of gene transcription. 
From our genome-wide analyses, we observed that the occupancy of ASXL1 was 
mostly confined to the distal intergenic regions. However, a significant portion of 





Furthermore, aggregate plot analyses also revealed that the highest enrichment of 
ASXL1 was observed near the TSS region of the genes. Possible mechanistic 
explanations for the presumed tumor-suppressor activity of ASXL1 can be studied by 
identifying the ASXL1 regulated genes. In our IGV data significant ASXL1 peaks 
were found around the promoter regions of a small subset of ASXL1 regulated genes 
such as PTEN, TJP3 and ARID1B. Furthermore, the qRT-PCR analysis showed that 
there was a significant decrease of ASXL1 binding on the TSS of PTEN, ARID1B 
and TJP3 upon ASXL1 knockdown. Moreover, there was a significant increase in 
ASXL1 occupancy upon ASXL1 overexpression which proves the specificity of 
ASXL1.  
A key issue that remains to be elucidated is whether ASXL1 binding has a direct 
function in gene transcription. Indeed, we observed that these genes were 
significantly downregulated upon ASXL1 depletion and upregulated upon ASXL1 
overexpression. These results demonstrate that ASXL1 regulates gene transcription. 
5.5 ASXL1 regulates EMT by targeting PTEN 
PTEN, a tumor suppressor gene, is a negative regulator of (PI3K)-Akt pathway and 
participates in the regulation of cell cycle, proliferation, apoptosis, cell adhesion and 
EMT during embryonic development and cancer progression. PTEN is known to 
dephosphorylate Akt and inactivate PI3K/Akt pathway and its depletion leads to 
accumulation of an active form of Akt (Cantley and Neel 1999, Nicholson, Streuli et 
al. 2003). PTEN mutations were reported in several cancers and its loss leads to 
induction of tumor invasion and metastasis (Wang, Quah et al. 2007, Keniry and 
Parsons 2008, Bao, Yan et al. 2013).  In our ChIP-seq analysis, we found that 





depending upon ASXL1 expression. Thus, loss of PTEN perturbs the EMT genes. As 
a result of depletion of PTEN in MCF10A and MDA-MB-231 cells, the expression of 
epithelial markers, CDH1 and TJP3 were downregulated and mesenchymal markers, 
CDH2, VIM and FN1 were upregulated without any effect on the expression of 
ASXL1. Thus, this indicates that PTEN may be one of the main downstream 
regulators of ASXL1. However, the ectopic expression of ASXL1 was able to 
suppress the expression of mesenchymal markers and retain the expression of 
epithelial markers. Furthermore, p-Akt was increased upon ASXL1 depletion 
whereas decreased upon ASXL1 overexpression. As PTEN is a downstream 
regulator of ASXL1, knockdown of PTEN in ASXL1 overexpressing MDA-MB-231 
cells rescued the phosphorylation of Akt.  Thus, our results suggest that ASXL1 
inhibits Akt signaling through positive regulation of PTEN expression.  
5.6 ASXL1 and post-translational modifications 
It was reported that ASXL1 regulates epigenetic marks and transcription through 
interaction with polycomb complex proteins, thus ASXL1 loss results in the reduction 
of K3K27me3, the repressive mark regulated by the PRC2 complex (Cho, Kim et al. 
2006, Boultwood, Perry et al. 2010, Wang, Li et al. 2014). It was also reported that 
ASXL1 depletion disrupts the PR-DUB complex which in turn results in an increase 
in H2Aub1 levels. In our study, we show that depletion of ASXL1 is associated with 
global changes in histone modifications such as decreased levels of global 
H3K4me3 levels and increased levels of global H2Aub1 levels. We also observed 
that there is a slight reduction of H2Bub1 levels. However, H3K27me3 levels were 
not affected. Global loss of H2Bub1 has been reported in breast cancer (Prenzel, 





complex, which is involved in H3K4 methylation (Wood, Schneider et al. 2005, Kim, 
Guermah et al. 2009). H3K4me3 is associated with transcription activation and 
enrichment of ASXL1 at promoter regions genome-wide suggesting the potential role 
of that ASXL1 in the regulation of gene transcription.  
5.7 Loss of ASXL1 is associated with occupancy of H3K4me3 
As it was observed in this study, depletion of ASXL1 leads to a reduction in global 
H3K4me3 levels. Therefore, the H3K4me3 binding on various direct ASXL1 target 
genes (PTEN, TJP3, and ARID1B) following ASXL1 knockdown and overexpression 
was analyzed. Our ChIP-qRT-PCR in ASXL1 depleted cells revealed a significant 
reduction of H3K4me3 enrichment on ASXL1 target genes whereas ASXL1 
overexpression showed increased occupancy of H3K4me3. Furthermore, aggregate 
plot analyses of publicly available ChIP-seq data for H3K4me3 showed that the 
highest enrichment of H3K4me3 was observed near the TSS region of the ASXL1 
bound genes. Our data suggests that ASXL1 target genes expression was altered 
through direct binding and also by altering the chromatin state of promoters. 
5.8 ASXL1 physically interacts with BAP1 and SET1 methyltransferase 
complex members 
Recent studies have identified several interacting partners for ASXL family members, 
such as BAP1, PRC2 complex members (EZH2 and EED) and nuclear receptors 
(Cho, Kim et al. 2006, Scheuermann, de Ayala Alonso et al. 2010, Park, Yoon et al. 
2011, Lai and Wang 2013). In this study, we showed that ASXL1 depletion leads to 
the reduction in both global and promoter-associated H3K4me3. Our results clearly 
demonstrate that ASXL1 interacts with BAP1, Cfp1 and Wdr82, whereas BAP1 





deubiquitinates the H2Aub1.  Furthermore, our studies demonstrated for the first 
time that ASXL1 physically interact with SET1 complex members. Taken together, 
our results indicate that ASXL1 may form a complex with SET1 complex members 
and co-regulate target gene expression in part through H3K4me3.  
5.9 ASXL1 regulates expression of SET1 complex members  
It was reported that BAP1 not only interacts with HCF1 but also deubiquitinates 
HCF1, which is a member of SET1 complex and is involved in the recruitment of 
Setd1A and MLL1, which leads to transcription activation through H3K4me3 (Lee, 
Tate et al. 2007, Narayanan, Ruyechan et al. 2007, Tyagi, Chabes et al. 2007, 
Machida, Machida et al. 2009). Our results show that SET1 complex members were 
interacting with ASXL1 and BAP1. Interestingly, we also observed the expression of 
Wdr82 was significantly decreased whereas Cfp1 expression was partially 
decreased upon ASXL1 depletion. Furthermore, we also observed increased 
expression of Wdr82, but there was no change in Cfp1 expression upon ASXL1 
overexpression. It was reported that depletion of Wdr82 leads to decreased 
expression of Setd1A, which in turn leads to the decreased H3K4me3 at the TSS as 
a result of decreased occupancy of Setd1A. It was also reported that depletion of 
Wdr82 downregulates Set1A expression and effects the stability of SET1 complex 
(Lee and Skalnik 2008, Wu, Wang et al. 2008). Our data suggests that ASXL1 
mediates the expression of SET1 complex members and regulates H3K4me3 
through SET1 complex. 
 




6. Conclusion and Future Perspectives 
Altogether, in this study, we have elucidated the tumor suppressor role of ASXL1 in 
breast cancer, which inhibits EMT and regulates stem cell properties in mammary 
cells. RNA-seq analysis revealed that the loss of ASXL1 results in upregulation of 
EMT gene signatures and also induces migratory properties. Furthermore, based on 
the genome-wide and transcriptome-wide analysis, we found PTEN as a direct target 
gene of ASXL1 and depletion of PTEN leads to EMT phenotype. Interestingly, we 
also found that ASXL1 interacts with a methyltransferase, SET1 complex members 
and their expression were also regulated by ASXL1. More studies are required to 
further validate the mechanism and regulatory function of ASXL1 that is coupled with 
transcription and EMT. Furthermore, ChIP analysis or ChIP-seq against SET1 
complex members to determine genome-wide co-occupancy of ASXL1 and SET1 
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